WO2022145490A1 - iPS細胞を介する再生T細胞の製造方法 - Google Patents
iPS細胞を介する再生T細胞の製造方法 Download PDFInfo
- Publication number
- WO2022145490A1 WO2022145490A1 PCT/JP2021/049028 JP2021049028W WO2022145490A1 WO 2022145490 A1 WO2022145490 A1 WO 2022145490A1 JP 2021049028 W JP2021049028 W JP 2021049028W WO 2022145490 A1 WO2022145490 A1 WO 2022145490A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- ips
- cancer
- hematopoietic stem
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 33
- 210000004027 cell Anatomy 0.000 claims abstract description 396
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 386
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 166
- 238000000034 method Methods 0.000 claims abstract description 152
- 108091007433 antigens Proteins 0.000 claims abstract description 120
- 102000036639 antigens Human genes 0.000 claims abstract description 120
- 239000000427 antigen Substances 0.000 claims abstract description 119
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 70
- 210000002861 immature t-cell Anatomy 0.000 claims abstract description 48
- 230000004069 differentiation Effects 0.000 claims abstract description 41
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 40
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 claims abstract description 37
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims abstract description 37
- 239000002299 complementary DNA Substances 0.000 claims abstract description 37
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 18
- 230000035755 proliferation Effects 0.000 claims abstract description 3
- 108091008874 T cell receptors Proteins 0.000 claims description 112
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 73
- 201000011510 cancer Diseases 0.000 claims description 68
- 238000011282 treatment Methods 0.000 claims description 27
- 239000013598 vector Substances 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 239000013603 viral vector Substances 0.000 claims description 21
- 108091033409 CRISPR Proteins 0.000 claims description 19
- 238000013411 master cell bank Methods 0.000 claims description 19
- 238000003860 storage Methods 0.000 claims description 16
- 238000010362 genome editing Methods 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 238000010354 CRISPR gene editing Methods 0.000 claims description 10
- 208000006359 hepatoblastoma Diseases 0.000 claims description 9
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 9
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 9
- 108010047620 Phytohemagglutinins Proteins 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 230000001885 phytohemagglutinin Effects 0.000 claims description 8
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 7
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 7
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims description 7
- 102100039564 Leukosialin Human genes 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 238000005138 cryopreservation Methods 0.000 claims description 7
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 5
- 108010056030 retronectin Proteins 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 210000003757 neuroblast Anatomy 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 238000010459 TALEN Methods 0.000 claims description 3
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 230000008672 reprogramming Effects 0.000 abstract description 15
- 230000009257 reactivity Effects 0.000 abstract description 7
- 108090000623 proteins and genes Proteins 0.000 description 72
- 239000001963 growth medium Substances 0.000 description 63
- 230000014509 gene expression Effects 0.000 description 25
- 239000003550 marker Substances 0.000 description 24
- 210000001616 monocyte Anatomy 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 20
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 18
- 239000002609 medium Substances 0.000 description 18
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 17
- 238000012258 culturing Methods 0.000 description 17
- 238000009256 replacement therapy Methods 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 16
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 16
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 description 15
- 210000005259 peripheral blood Anatomy 0.000 description 14
- 239000011886 peripheral blood Substances 0.000 description 14
- 102100037850 Interferon gamma Human genes 0.000 description 13
- 108010074328 Interferon-gamma Proteins 0.000 description 13
- 210000005087 mononuclear cell Anatomy 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 description 12
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 12
- 238000012546 transfer Methods 0.000 description 12
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 102100032530 Glypican-3 Human genes 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 10
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 description 10
- 229940088594 vitamin Drugs 0.000 description 10
- 229930003231 vitamin Natural products 0.000 description 10
- 235000013343 vitamin Nutrition 0.000 description 10
- 239000011782 vitamin Substances 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 235000010633 broth Nutrition 0.000 description 8
- -1 c-Met Proteins 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 8
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 6
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 6
- 241000711408 Murine respirovirus Species 0.000 description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 6
- 102000036693 Thrombopoietin Human genes 0.000 description 6
- 108010041111 Thrombopoietin Proteins 0.000 description 6
- 210000004102 animal cell Anatomy 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000008707 rearrangement Effects 0.000 description 6
- 238000004114 suspension culture Methods 0.000 description 6
- 150000003722 vitamin derivatives Chemical class 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 108060005980 Collagenase Proteins 0.000 description 5
- 102000029816 Collagenase Human genes 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- 102000001301 EGF receptor Human genes 0.000 description 5
- 108060006698 EGF receptor Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- 239000012826 P38 inhibitor Substances 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 229960002424 collagenase Drugs 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
- 108091035539 telomere Proteins 0.000 description 5
- 210000003411 telomere Anatomy 0.000 description 5
- 102000055501 telomere Human genes 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 4
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
- 108020005004 Guide RNA Proteins 0.000 description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 4
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 4
- 108010002586 Interleukin-7 Proteins 0.000 description 4
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 4
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 4
- 101150086694 SLC22A3 gene Proteins 0.000 description 4
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 210000002242 embryoid body Anatomy 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000000700 radioactive tracer Substances 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 3
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 3
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 102100026964 M1-specific T cell receptor beta chain Human genes 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- 108090000848 Ubiquitin Proteins 0.000 description 3
- 102000044159 Ubiquitin Human genes 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000016571 aggressive behavior Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 210000003722 extracellular fluid Anatomy 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 3
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 235000011649 selenium Nutrition 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000009258 tissue cross reactivity Effects 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- JBNWDYGOTHQHOZ-UHFFFAOYSA-N 2-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-6-methoxy-1-methylindol-3-yl]-n,n-dimethyl-2-oxoacetamide Chemical compound COC1=CC=2N(C)C=C(C(=O)C(=O)N(C)C)C=2C=C1C(=O)N(CC1)CCC1CC1=CC=C(F)C=C1 JBNWDYGOTHQHOZ-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108010008655 Epstein-Barr Virus Nuclear Antigens Proteins 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 150000000996 L-ascorbic acids Chemical class 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZQUSFAUAYSEREK-WKILWMFISA-N SB-239063 Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)[C@@H]2CC[C@@H](O)CC2)=N1 ZQUSFAUAYSEREK-WKILWMFISA-N 0.000 description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 2
- 108700020467 WT1 Proteins 0.000 description 2
- 101150084041 WT1 gene Proteins 0.000 description 2
- 102100022748 Wilms tumor protein Human genes 0.000 description 2
- MIJPAVRNWPDMOR-UHFFFAOYSA-N [2-(1,2-dihydroxyethyl)-3-hydroxy-5-oxo-2h-furan-4-yl] dihydrogen phosphate Chemical compound OCC(O)C1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 108010076089 accutase Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000008211 brain sarcoma Diseases 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 101150058049 car gene Proteins 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013000 chemical inhibitor Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000012737 microarray-based gene expression Methods 0.000 description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- BVYZDBLMCKSKAT-UHFFFAOYSA-N 2,2,3,3-tetrahexyldecanoic acid Chemical compound CCCCCCCC(CCCCCC)(CCCCCC)C(CCCCCC)(CCCCCC)C(O)=O BVYZDBLMCKSKAT-UHFFFAOYSA-N 0.000 description 1
- RQVKVJIRFKVPBF-VWLOTQADSA-N 2-[[(2s)-2-amino-3-phenylpropyl]amino]-3-methyl-5-naphthalen-2-yl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C([C@H](N)CNC=1N(C(C(C=2C=C3C=CC=CC3=CC=2)=C(C=2C=CN=CC=2)N=1)=O)C)C1=CC=CC=C1 RQVKVJIRFKVPBF-VWLOTQADSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- UCWMQLDNYHPJJE-UHFFFAOYSA-N 4-[1-(4-fluorophenyl)-5-pyridin-4-ylimidazol-2-yl]phenol Chemical compound FC1=CC=C(C=C1)N1C(=NC=C1C1=CC=NC=C1)C1=CC=C(C=C1)O UCWMQLDNYHPJJE-UHFFFAOYSA-N 0.000 description 1
- XEOVWJYINDYNSM-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)-1H-imidazol-5-yl]pyridine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 XEOVWJYINDYNSM-UHFFFAOYSA-N 0.000 description 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- 102100022907 Acrosin-binding protein Human genes 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150018757 CD19 gene Proteins 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- 108010032795 CD8 receptor Proteins 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100510259 Caenorhabditis elegans klf-2 gene Proteins 0.000 description 1
- 101100257372 Caenorhabditis elegans sox-3 gene Proteins 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101100193633 Danio rerio rag2 gene Proteins 0.000 description 1
- 102100033553 Delta-like protein 4 Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 208000020402 Enthesitis-related juvenile idiopathic arthritis Diseases 0.000 description 1
- 102000051096 EphA2 Receptor Human genes 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 108010069621 Epstein-Barr virus EBV-associated membrane antigen Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101100005249 Escherichia coli (strain K12) ygcB gene Proteins 0.000 description 1
- 101150099612 Esrrb gene Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 1
- 101000756551 Homo sapiens Acrosin-binding protein Proteins 0.000 description 1
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 1
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 description 1
- 101000972278 Homo sapiens Mucin-6 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 description 1
- 101000666295 Homo sapiens X-box-binding protein 1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 102000016200 MART-1 Antigen Human genes 0.000 description 1
- 108700002010 MHC class II transactivator Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 102100022496 Mucin-5AC Human genes 0.000 description 1
- 102100022493 Mucin-6 Human genes 0.000 description 1
- 101000804949 Mus musculus Developmental pluripotency-associated protein 2 Proteins 0.000 description 1
- 101100193635 Mus musculus Rag2 gene Proteins 0.000 description 1
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 1
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 1
- 101100257376 Mus musculus Sox3 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 101150072008 NR5A2 gene Proteins 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 101150012848 PVR gene Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100037686 Protein SSX2 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 101150001847 Sox15 gene Proteins 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108700042077 T-Cell Receptor beta Genes Proteins 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 101150111019 Tbx3 gene Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000566576 Tyto Species 0.000 description 1
- 102100039490 X antigen family member 1 Human genes 0.000 description 1
- 102100038151 X-box-binding protein 1 Human genes 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 101150055191 cas3 gene Proteins 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- MVCOAUNKQVWQHZ-UHFFFAOYSA-N doramapimod Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MVCOAUNKQVWQHZ-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000021601 lentivirus infection Diseases 0.000 description 1
- 101150111214 lin-28 gene Proteins 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- LUYQYZLEHLTPBH-UHFFFAOYSA-N perfluorobutanesulfonyl fluoride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)S(F)(=O)=O LUYQYZLEHLTPBH-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 102220225485 rs1064793217 Human genes 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000007860 single-cell PCR Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0278—Physical preservation processes
- A01N1/0284—Temperature processes, i.e. using a designated change in temperature over time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464401—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464474—Proteoglycans, e.g. glypican, brevican or CSPG4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
Definitions
- the present invention introduces a T cell receptor obtained from a CD106-positive T cell population into non-T non-B cells or iPS cells derived from monocytes or T cells to produce tumor antigen-specific regenerated T cells.
- T cells play a central role in the immune response to foreign pathogens such as bacteria or viruses or abnormal cells such as cancer cells. Therefore, it is considered that the functional deterioration of T cells contributes to pathogen infection and the development of cancer.
- T cell replacement therapy or regenerative therapy for a patient having a disease caused by a decrease in T cell function can be an extremely effective means for improving or treating the pathological condition of the disease in the patient.
- T cell replacement therapy for infectious diseases or cancer specifically recognizes antigens possessed by foreign pathogens such as bacteria or viruses or abnormal cells such as cancer cells. It is known that a high therapeutic effect can be obtained by using T cells. On the other hand, it is difficult to secure a sufficient amount of T cells, and exhaustion of T cells such as a decrease in proliferative ability in T cells and a decrease in immune response to antigens such as target cells becomes obstacles in T cell replacement therapy. ing. Also, how to obtain tumor-specific T cells is a major issue.
- iPS cells artificial pluripotent stem cells
- Cell replacement therapy has been proposed. Since the T cell receptor (TCR) for recognizing the target antigen is formed by gene rearrangement of the genome, the TCR gene possessed by the T cell before reprogramming is conserved in the iPS cell in which the T cell is reprogrammed. Has been done. Therefore, by using T cells specific to the target antigen as a raw material for producing iPS cells, it is possible to produce regenerated T cells exhibiting the same antigen specificity as the original T cells. (Patent Document 1 and Non-Patent Document 1).
- Non-Patent Document 2 Strict antigen specificity is required for safe and efficient T cell replacement therapy.
- Patent Document 2 It has been reported that in regenerated T cells obtained from T cells via iPS cells as described above, the frequency of appearance of T cells having the same gene rearrangement pattern as the original T cells is not necessarily high.
- Patent Document 2 It has also been reported that CD8 ⁇ regenerated T cells obtained from human T cells via iPS cells lose antigen specificity due to additional rearrangement of the TCR ⁇ chain gene at the CD4 / CD8 double positive stage.
- Nishimura T et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation.
- Minagawa A et al. Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy.
- iPS-T cells regenerated T cells
- iPS-T cells regenerated T cells
- tumor cells or tumor tissues can be used. It is important to ensure the safety and efficacy of iPS-T cell replacement therapy in the treatment of cancer.
- iPS-T cell replacement therapy when the onset or recurrence of cancer is detected, it is important to start iPS-T cell replacement therapy promptly in order to improve the treatment results.
- An object of the present invention is to provide a method for rapidly producing TCR-introduced iPS-T cells isolated from tumor tissue infiltrating CD106-positive T cells and iPS-T cells produced by the method. Furthermore, it is an object of the present invention to provide iPS-T cells produced by the method, a pharmaceutical composition containing the iPS-T cells, and a method for preventing or treating cancer using the pharmaceutical composition. ..
- T cell clones (5-10 clones) recognize antigens using different TCRs even for one antigen epitope.
- the possibility that the clone differentiated to iPS-T cells is a T cell clone with optimal TCR to damage the target is also due to individual differences in the subjects who collect the cells for producing iPS-T cells or iPS. -Affected by T cell production batches.
- T cells that specifically recognize a tumor it is necessary to administer the tumor antigen to a patient or co-culture the T cell and the tumor antigen in vitro, but the tumor antigen is used. If uncertain, it is extremely difficult to adopt such a method.
- the CD106-positive T cell population isolated from tumor tissue is a T cell population that recognizes tumor-related antigens and has specific aggression against cancer cells.
- iPS-T cells can be obtained by obtaining various TCR pools with antigen specificity, and by introducing TCR into non-T non-B cells or iPS cells established from monospheres or T cells.
- the iPS-T cells can be rapidly produced, and the TCR pool and the non-T non-B cells or monospheres or T cells of the same origin or in separate bodies. We have found that it is possible to have it, and have completed the present invention.
- T cell receptors obtained from a subject which are reactive to tumor-related antigens and which have a T cell receptor ⁇ chain and ⁇ chain for each single cell from a CD106-positive T cell population, respectively.
- the process of preparing the cDNA to be encoded (2) Peripheral blood mononuclear cells of the subject, from which B cells and T cells have been removed, are initialized into iPS cells, and the obtained iPS cells are differentiated into T cells.
- Steps to select high iPS cell clones (3) A step of introducing the cDNA into the iPS cell clone, a hematopoietic stem cell differentiated from the iPS cell clone, an immature T cell differentiated from the hematopoietic stem cell, or a mature T cell differentiated from the immature T cell, and (4). ) The step of differentiating the iPS cell clone into which the cDNA has been introduced, the hematopoietic stem cell or the immature T cell into mature T cells, and the proliferation of the mature T cells obtained in step (3). A method for producing regenerated T cells via iPS cells.
- the present invention comprises a step of selecting T cells having no allo-reaction with respect to cells derived from a subject who is a target for cancer prevention or treatment from the T cells into which the cDNA obtained in step (4) has been introduced.
- it comprises a step of selecting a cDNA encoding a T cell receptor that does not induce an allo reaction to cells derived from a subject to be prevented or treated for cancer from the cDNA prepared in step (1).
- step (3) introduction of the cDNA into the iPS cell clone, the hematopoietic stem cell differentiated from the iPS cell clone, the immature T cell differentiated from the hematopoietic stem cell, or the mature T cell differentiated from the immature T cell.
- a viral vector or a non-viral vector is used, or a genome editing technique is used.
- step (4) the steps of differentiating the iPS cell clone into which the cDNA has been introduced, the hematopoietic stem cell or the immature T cell into mature T cells, and proliferating the mature T cells are the feeder cells and PHA (phytohemagglutinin).
- Retronectin® and anti-CD3 antibody In the presence of Retronectin® and anti-CD3 antibody, or in the presence of anti-CD3 antibody and anti-CD28 antibody, according to any one of [1] to [13].
- the feeder cells are autologous or allogeneic peripheral blood mononuclear cells.
- the subject in step (1) or (2) is hepatocellular carcinoma, hepatoblastoma, gastric cancer, esophageal cancer, lung cancer, pancreatic cancer, renal cell carcinoma, breast cancer, ovarian cancer, malignant melanoma, etc.
- the highly immunogenic cancer is hepatocellular carcinoma, hepatoblastoma, colon cancer, lung cancer or malignant melanoma.
- iPS-T cells regenerated T cells
- peripheral blood mononuclear cells non-T non-B cells or monocytes
- T cells from which T cells and B cells have been removed are initially used.
- iPS cell clones having good differentiation efficiency into T cells are selected in advance. Therefore, it is possible to secure a sufficient amount of iPS-T cells required for treatment according to the timing required for treatment.
- iPS cell clones derived from non-T non-B cells or monocytes or T cells hematopoietic stem cells differentiated from the iPS cell clones, immature T cells differentiated from the hematopoietic stem cells or the immature T cells.
- TCR TCR antigen
- iPS cell clones with good differentiation efficiency into T cells are selected and used, so that the yield and degree of differentiation vary between iPS-T cell production batches, and the cells are used. It is possible to minimize the influence of individual differences of the subjects to be collected on the quality and the like of the obtained iPS-T cells. In addition, it becomes possible to efficiently produce T cells having a TCR that recognizes an antigen and efficiently kills a target.
- the cDNA encoding the TCR is prepared for each single cell from the T cell population having genetic diversity, it is possible to prepare a cDNA group having various antigen specificities. .. Since the CD106-positive T cell population isolated from the tumor tissue is a T cell population that recognizes the tumor antigen, the tumor antigen-induced immunity or in vitro T cells are used to isolate the tumor-specific TCR in advance. There is no need for co-culture with tumor antigens. Therefore, according to the method of the present invention, the production period of iPS-T cells is shortened, and at the same time, tumor-specific iPS-T cells are produced even when the tumor antigen in a cancer patient is unknown. It is possible.
- non-T non-B cell or monocyte-derived or T cell-derived iPS cell clones is performed prior to the preparation of the cDNA encoding the antigen-specific TCR or in parallel with the preparation of the cDNA. Therefore, iPS-T cells can be produced in a short period of time as compared with the method of sequentially performing these. Therefore, in cancer treatment to which iPS-T cell replacement therapy is applied, it is specific to the expressed antigen for tumor antigen change or development of treatment resistance or cancer recurrence in the cancer patient to be treated. It is possible to quickly prepare various iPS-T cells.
- the subject from which the T cells used for preparing the cDNA encoding the TCR are collected is the same individual as the subject who is a cancer patient to be treated by iPS-T cell replacement therapy. It may be separate from each other. Therefore, it is possible to prepare a TCR pool corresponding to various antigens, and it is possible to select a TCR having optimal antigen specificity for each cancer patient.
- the upper partial view shows a step of isolating the TCR gene from CD106-positive T cells and a step of verifying antigen-specific reactivity
- the lower partial view shows a step of producing a TCR gene-introduced iPS cell and a step of producing the TCR gene-introduced iPS cell.
- the step of producing the regenerated T cell from the iPS cell is shown. It is a figure which shows the step of introducing a TCR gene using a piggyBac® transposon vector. It is a figure which shows the phenotype of the regenerated T cell (tumor-related antigen-specific CD8 positive cytotoxic T cell) derived from iPS cell. It is a figure which shows the result of having analyzed the telomere as a cell senescence marker in a regenerated T cell. It is a figure which shows the result of having analyzed the expression of PD-1 and TIGHT molecules as a cell exhaustion marker in regenerated T cells.
- IL-2 and IFN- ⁇ levels produced by stimulation with PMA and ionomycin in cytotoxic T cells (CD8 ⁇ chain / ⁇ chain double positive cells) and regenerated T cells in peripheral blood mononuclear cells of healthy subjects It is a figure. It is a figure which shows the expression of various markers in a tumor infiltrating T cell. In each panel, cells positive for the expression of the markers described within the panel are shown colored. The cells are clustered according to the expression pattern, and the circled part corresponds to the tumor-damaging T cell. It is a figure which shows the IFN- ⁇ production at the time of self-tumor stimulation in the cell subpopulation that tumor infiltrated T cells were sorted by marker expression.
- IFN- ⁇ is produced by autotumor stimulation
- marker-positive cell subpopulation other than CD106 IFN- ⁇ is produced by autotumor stimulation, but the marker-negative cell subpopulation. Since IFN- ⁇ is also produced in the population, it can be understood that the specificity is inferior to that of CD106.
- the CD19 gene is a gene integrated into the same piggyBac® transposon vector in tandem with the TCR gene, and is used as a marker for gene insertion into the host chromosome and gene expression.
- the "T cell” obtained from a subject is a cell expressing an antigen receptor called a T cell receptor (TCR) on the cell surface.
- TCR includes a heterodimer consisting of an ⁇ chain and a ⁇ chain, and a heterodimer consisting of a ⁇ chain and a ⁇ chain.
- T cells having a TCR consisting of an ⁇ chain and a ⁇ chain are called ⁇ type T cells, and T cells having a TCR consisting of a ⁇ chain and a ⁇ chain are called ⁇ type T cells.
- the T cells of the present invention are preferably CD3 / ⁇ type T cells, but may be CD3 / ⁇ type T cells.
- the TCR of T cells in the present invention is a gene-introduced one.
- the "T cell population” refers to the above-mentioned T cell population in which the gene sequence of the T cell receptor (TCR) that recognizes an antigen is diverse as a whole. Therefore, T cells collected from a living body are a T cell population having specificity for various antigens. In the T cells existing in the living body, each T cell has a different TCR gene sequence due to the random recombination of the TCR gene when the T precursor cells develop and differentiate in the thymus, and for all antigens. It is possible to provoke an immune response.
- CD106 is a highly specific marker for identifying T cells having aggression against cancer cells, and the TCR possessed by each CD106-positive T cell is tumor antigen-specific. Therefore, by treating CD106-positive T cells as a population, it can be understood that the T cell population is immune to various tumor antigens. Therefore, the CD106-positive T cell population collected from a living body is a T cell population having genetic diversity in that sense.
- the "tumor-related antigen” is an antigen that is specifically or non-specifically expressed in a tumor, and is an antigen derived from a protein that is overexpressed in tumor cells and a variant thereof, an antigen derived from a tumor virus, and the like. Certain differentiation antigens and novel tumor-related antigens (neoantigens) due to gene mutations and splice abnormalities. T cells that respond to "tumor-related antigens" are recognized as CD106-positive T cells.
- a tumor-related antigen may be referred to as a tumor antigen. When it is a protein antigen, it may be a peptide fragmented from this (peptide fragment).
- Antigens expressed specifically or non-specifically to tumors include WT1, GPC3, XAGE1, MUC1, MUC5AC, MUC6, EGFRvIII, HER-2 / neu, MAGE A3, MAGE A1, telomerase, PRAME, SSX2 / 4, PSCA. , CTLA-4, gp100, GD2, GD3, fucosyl GM1, GM3, sLe (a), glycolipid F77, mesotelin, PD-L1, trp1, trp2, CD19, CD20, CD22, ROR1, CD33, c-Met, p53.
- Viral antigens include inactivated viruses such as inactivated HBV and HPV, and proteins derived from various viruses EBV LMP1, EBV LMP2, EBNA (EBV nuclear antigen), HPV E1, HPV E2, HPV E6, HPV E7, HBV. Examples include, but are not limited to, HBs, HTLV-1Tax, HBZ (HTLV-1bZIPFactor), and the like.
- T cells are tumor-related presented to major histocompatibility complex (MHC) class I or class II on antigen-presenting cells. It means that T cells have a reaction caused by selectively binding / joining to an epitope peptide derived from an antigen via TCR, and in binding / joining of T cells to something other than the epitope peptide, the T cells It means that no reaction occurs.
- MHC major histocompatibility complex
- the T cell response resulting from binding / conjugation to an epitope peptide derived from a tumor-related antigen presented in MHC class I or class II via the TCR is cytotoxic, IFN- ⁇ and granzyme production, T. Expression of cell activation markers and activation of transcription factors such as NF-AT can be mentioned.
- the T cells are preferably ⁇ T cells.
- the source of T cells is preferably, but not limited to, peripheral blood because of its low invasiveness.
- Other preferred sources are cancer or tumor tissue, lymph nodes or other tissues or organs, or blood, umbilical cord blood, lymph, tissue fluid (interstitial fluid, interstitial fluid and interstitial fluid), body cavity fluid (abdominal fluid). , Chest fluid, heart sac fluid, cerebrospinal fluid, joint fluid and atriointerstitial fluid) and all sources in the body.
- preferred T cells are tumor tissue-derived T cells. Tumor tissue-derived T cells are usually tumor-infiltrating T cells.
- the cancer of the cancer patient is hepatocellular carcinoma, hepatoblastoma, gastric cancer, esophageal cancer, lung cancer, pancreatic cancer, renal cell carcinoma, breast cancer, ovarian cancer, Skin cancer such as malignant melanoma, bladder cancer, head and neck cancer, uterine cancer, cervical cancer, glioblastoma, prostate cancer, neuroblast tumor, chronic lymphocytic leukemia, papillary thyroid cancer, colon Selected from cancer, brain tumor, sarcoma or B-cell non-Hodgkin lymphoma.
- the cancer is preferably hepatocellular carcinoma or hepatoblastoma.
- iPS cells are preferably produced by reprogramming non-T non-B cells or monocytes or T cells, but are not limited to non-T non-B cells or monocytes or T cells.
- Non-T non-B cell means a mononuclear cell that is not classified as a T cell and is not classified as a B cell.
- non-T non-B cells or monocytes can be prepared by collecting as peripheral blood mononuclear cells of a subject and then removing T cells and B cells contained in the mononuclear cells. Peripheral blood mononuclear cells can be isolated from whole human blood with a mononuclear cell isolation solution.
- Examples of the mononuclear cell separation solution include Lymphoprep (registered trademark).
- B cells such as CD19, CD20, CD22 or B cell receptors
- T cells such as CD3, CD4 or CD8.
- the antibody may be utilized to use magnetic beads such as, for example, flow cytometry or MACS® beads.
- T cells can be isolated from whole human blood with a mononuclear cell isolation solution.
- Examples of the mononuclear cell separation solution include Lymphoprep (registered trademark). Purification of T cells can be performed by utilizing the surface antigens of T cells, CD3, CD4 or CD8, or T cell receptors. Magnetic beads such as, for example, flow cytometry or MACS® beads may be used.
- iPS cells can preferably be induced by introducing a cell reprogramming factor into non-T non-B cells or monocytes or T cells.
- cell reprogramming factors include Oct3 / 4, Sox2, Sox1, Sox3, Sox15, Sox17, klf4, klf2, c-Myc, N-Myc, L-Myc, Nanog, Lin28, Fbx15, ERAs, and ECAT15-2.
- cell reprogramming factors may be used alone or in combination.
- these cell reprogramming factors from the viewpoint of efficiently establishing iPS cells, Oct3 / 4, Sox2, Klf4 and c-Myc (so-called Yamanaka 4 factors) are used as the non-T non-B cells or monocytes. Alternatively, it is preferably introduced into T cells.
- the method for introducing a cell reprogramming factor into the non-T non-B cell or monocyte or T cell is not particularly limited, and a method known in the art can be adopted.
- the gene encoding the cell reprogramming factor for example, cDNA
- the gene encoding the cell reprogramming factor is introduced into the non-T non-B cell or monocyte. It is inserted into an expression vector containing a promoter that functions in spheres or T cells, and the expression vector is subjected to non-T by infection, lipofection method, liposome method, calcium phosphate co-precipitation method, DEAE dextran method, microinjection method or electroporation method.
- the cell reprogramming factor can be introduced into non-B cells or monocytes or T cells.
- the cell reprogramming factor is in the form of a protein and the protein is introduced into the non-T non-B cells or monospheres or T cells, a method using a protein transfer reagent or a method using a protein transfer domain fusion protein. , Electroporation method and microinjection method.
- mRNA messenger RNA
- a method using an mRNA introduction reagent and a method of adding the mRNA to the culture medium are available. Can be mentioned.
- the expression vector used for gene transfer by infection examples include viral vectors such as lentivirus, retrovirus, adenovirus, adeno-associated virus, herpesvirus, and Sendai virus, and animal cell expression plasmids, but insertion mutations are unlikely to occur.
- viral vectors such as lentivirus, retrovirus, adenovirus, adeno-associated virus, herpesvirus, and Sendai virus
- animal cell expression plasmids but insertion mutations are unlikely to occur.
- the gene encoding the cell reprogramming factor is transferred to the non-T non-B cell or monosphere or T cell using Sendai virus. It is preferable to introduce it.
- Examples of the promoter used in the expression vector used when introducing the gene encoding the cell reprogramming factor into non-T non-B cells or monospheres or T cells include SR ⁇ promoter, SV40 promoter, LTR promoter, CMV promoter, and the like. Examples include the RSV promoter, HSV-TK promoter, ubiquitin promoter and the like. These promoters may be capable of controlling the expression of the gene inserted downstream of the promoter depending on the presence or absence of a drug such as tetracycline.
- the expression vector can include an enhancer, a poly A addition signal, a selectable marker gene (for example, a neomycin resistance gene), an SV40 origin of replication, and the like.
- the culture medium used for culturing iPS cells obtained by reprogramming non-T non-B cells or monocytes or T cells is not particularly limited, but the culture medium used for culturing animal cells is used as the basal culture medium. It can be prepared by adding cytokines for maintaining the undifferentiated ability of iPS cells.
- the basal culture medium include Isove's Modified Dulbecco's Medium (IMDM) culture medium, Medium 199 culture medium, Eagle's Minimum Essential Medium (EMEM) culture medium, ⁇ MEM culture medium, Dulbecco's modified Eagle's Medium (DMEM) culture medium, and Ham.
- IMDM Isove's Modified Dulbecco's Medium
- EMEM Eagle's Minimum Essential Medium
- DMEM Dulbecco's modified Eagle's Medium
- cytokines include bFGF, and the concentration thereof in the culture medium is, for example, 1 to 100 ⁇ g / mL (preferably 50 ⁇ g / mL).
- the method for culturing iPS cells may be adhesive culture or suspension culture, but adhesive culture is preferable.
- the method for isolating iPS cells include a method of physically isolating with a cell scraper or the like, a dissociation solution having protease activity, a dissociation solution having collagenase activity, or a dissociation solution having protease activity and collagenase activity (for example,).
- An isolation method using Accutase (registered trademark), Accumax (registered trademark), etc.) can be mentioned.
- the iPS cells are preferably 1 ⁇ 10 3 to 1 ⁇ 10 4 cells / cm 2 , 1 ⁇ 10 4 to 1 ⁇ 10 5 cells / cm 2 or 1 ⁇ 10 5 to 1 ⁇ 10.
- the number of passages may be any number as long as the required amount of iPS cells is obtained, preferably 1 to 5 times or 5 to 10 times.
- the produced iPS cells consist of a large number of iPS cell clones.
- the colony pickup method is not particularly limited, but a method using a pipette man under a microscope, a limiting dilution method, a method using a fully automated colony picker, and the like are used.
- the obtained iPS cell clone may form a master cell bank after expansion culture.
- the "master cell bank" composed of the iPS cell clones is a single pool of iPS cell clones that is dispensed and accumulated in an independent cell storage container.
- cryopreserve iPS cell clones In the master cell bank, it is preferable to cryopreserve iPS cell clones. Methods of cryopreserving cells are well known to those of skill in the art. For example, cultured iPS cell clones are collected, washed with a buffer or culture medium, the number of cells is counted, concentrated by centrifugation or the like, and suspended in a frozen medium (for example, a culture medium containing 10% DMSO). After turbidity, it can be cryopreserved at low temperature.
- the master cell bank of the present invention can be stored in any facility or storage that can be cryopreserved. In the case of cryopreservation, the storage temperature is not particularly limited as long as it is a temperature suitable for storing cells. For example, ⁇ 20 ° C., ⁇ 80 ° C. and ⁇ 120 to -196 ° C. are mentioned, but ⁇ 150 ° C. or lower is preferable.
- “Differentiation efficiency” refers to the hematopoietic stem cells, immature T cells, and mature T cells in all surviving cells at each stage of differentiation from iPS cells to hematopoietic stem cells, from hematopoietic stem cells to immature T cells, and from immature T cells to mature T cells, respectively. Refers to the abundance ratio. Identification of differentiated cells at each stage of differentiation can be performed by FACS analysis of surface markers. The efficiency of differentiation into hematopoietic stem cells is the proportion of CD34 / CD43 double positive cells in all viable cells, and the efficiency of differentiation into immature T cells is the proportion of CD4 / CD8 double positive cells or CD5 positive cells in all viable cells. Also, the efficiency of differentiation into mature T cells is shown as the proportion of cells in all surviving cells in which all of the CD8 ⁇ , CD8 ⁇ , TCR ⁇ and TCR ⁇ chains are positive.
- “High differentiation efficiency” or “good / good differentiation efficiency” means that the proportion of CD34 / CD43 double positive cells, which are hematopoietic stem cells, is 5 to 15% or more in the differentiation of iPS cells into hematopoietic stem cells. It means that the ratio of CD4 / CD8 double positive cells or CD5 positive cells, which are immature T cells, is 10% or more or 50% or more, respectively, in the differentiation of hematopoietic stem cells into immature T cells; In the differentiation from immature T cells to mature T cells, it means that the proportion of cells in which all of the CD8 ⁇ chain, CD8 ⁇ chain, TCR ⁇ chain and TCR ⁇ chain are positive is 50% or more.
- the regenerated T cells of the present invention preferably first differentiate the iPS cell clone into hematopoietic stem cells, then differentiate the hematopoietic stem cells into immature T cells, and finally the immature T cells into CD8 single positive T cells. It is produced by differentiating into mature T cells.
- the "hematopoietic stem cell” is a cell capable of differentiating into blood cell lineage cells such as lymphocytes, eosinophils, neutrophils, basophils, erythrocytes and megakaryocytes. It should be noted that hematopoietic stem cells and hematopoietic progenitor cells (HPC) are not distinguished and refer to the same cells unless otherwise specified. Hematopoietic stem cells / progenitor cells are recognized, for example, by the fact that the surface antigens CD34 and CD43 are double positive.
- the "immature T cell” is a T cell that expresses TCR ⁇ chain and ⁇ chain from the stage of T cell in which both TCR ⁇ chain and ⁇ chain are not expressed, and CD8 single via CD4 / CD8 double positive cell. Refers to T cells at each stage up to positive cells.
- the immature T cells are preferably CD8 ⁇ chain / ⁇ chain double positive.
- the "mature T cell” refers to a T cell that expresses a TCR ⁇ chain and a ⁇ chain and reaches a CD8 single positive cell via a CD4 / CD8 double positive cell.
- CD8 ⁇ chain / ⁇ chain double positive is preferable.
- Hematopoietic stem cells are preferably produced by culturing iPS cells in a culture medium supplemented with vitamin Cs.
- vitamin Cs refers to L-ascorbic acid and its derivatives
- L-ascorbic acid derivatives means those that are converted to vitamin C by an enzymatic reaction in the living body.
- L-ascorbic acid includes, for example, vitamin C phosphate, ascorbic acid glucoside, ascorbic ethyl, vitamin C ester, ascorbic tetrahexyldecanoate, ascorbic stearate and ascorbic acid-2 phosphate-6 palmitic acid.
- the derivative of L-ascorbic acid is preferably vitamin C phosphate, and examples thereof include phosphate-L ascorbate such as sodium phosphate-L ascorbate or magnesium phosphate-L-ascorbate.
- Vitamin Cs are contained, for example, in a culture solution at a concentration of 5 to 500 ⁇ g / mL.
- the culture medium used for producing hematopoietic stem cells is not particularly limited, but can be prepared by using the culture medium used for culturing animal cells as the basal culture medium and adding vitamin C or the like to it.
- the basal culture medium include Isove's Modified Dulbecco's Medium (IMDM) culture medium, Medium 199 culture medium, Eagle's Minimum Essential Medium (EMEM) culture medium, ⁇ MEM culture medium, Dulbecco's modified Eagle's Medium (DMEM) culture medium, and H12 culture medium.
- IMDM Isove's Modified Dulbecco's Medium
- EMEM Eagle's Minimum Essential Medium
- DMEM Dulbecco's modified Eagle's Medium
- H12 culture medium H12 culture medium.
- Examples include broth, RPMI 1640 broth, Fischer's broth, Neurobasal Medium (Life Technologies), StemPro34 (Life Technologies) and mixed broths thereof.
- the culture broth may contain serum or may be serum-free.
- the basal culture medium may be, for example, albumin, insulin, transferase, selenium, fatty acids, trace elements, 2-mercaptoethanol, thiolglycerol, monothiolglycerol, lipids, amino acids, L-glutamine, non-essential amino acids, vitamins. , Growth factors, low molecular weight compounds, antibiotics, antioxidants, pyruvate, buffers, inorganic salts, cytokines and the like.
- the culture medium used for the production of hematopoietic stem cells includes BMP4 (Bonemorphogenetic protein 4), VEGF (vascular endothelial growth factor), bFGF (basic fibroblast growth factor), SCF (stem cell factor), TPO (thrombopoietin), and FLT3L (FLT3L).
- Cytokines selected from the group consisting of Flt3 ligand) may be further added. These concentrations are, for example, 1-100 ng / mL for BMP4, 1-100 ng / mL for VEGF, 1-100 ng / mL for bFGF, and 10-100 ng / mL for SCF.
- TPO is 1 to 100 ng / mL
- FLT3L is 1 to 100 ng / mL.
- TGF ⁇ inhibitors are small molecule inhibitors that interfere with TGF ⁇ family signal transduction, such as SB431542 and SB202190 (R.K.Lindemann et al., Mol. Cancer 2: 20 (2003)), SB505124 (GlaxoSmithKline). , NPC30345, SD093, SD908 and SD208 (Scios), and LY2109761, LY364947 and LY580276 (Lilly Research Laboratories), and the concentration added to the culture solution is preferably 0.5 to 100 ⁇ M.
- iPS cells are C3H10T1 / 2 (Takayama N., et al. J Exp Med. 2817-2830, 2010) or heterologous stromal cells (Niwa A et al. J Ce11 Physiol. 2009 Nov; 221 (2): It may be co-cultured with feeder cells such as 367-77).
- the method for culturing iPS cells at the time of producing hematopoietic stem cells may be adhesive culture or suspension culture, but suspension culture is preferable.
- iPS cells can be subjected to suspension culture after releasing colonies cultured to 80% confluence with respect to the dish used, dissociating them into single cells.
- a method for isolating iPS cells for example, a method of physically isolating with a cell scraper or the like, a dissociation solution having protease activity and collagenase activity (for example, Accutase® and Accumax®), or An isolation method using a dissociation solution having collagenase activity can be mentioned.
- Floating culture is to culture cells in a non-adherent state to the culture vessel.
- the suspension culture is not particularly limited, but is a culture vessel that has not been artificially treated (for example, a coating treatment with an extracellular matrix or the like) for the purpose of improving adhesion to cells, or artificially suppresses adhesion. It can be carried out using a culture vessel which has been treated (for example, coated with polyhydroxyethyl methacrylate (po1y-HEMA) or a nonionic surfactant (Pluronic F-127, etc.)).
- po1y-HEMA polyhydroxyethyl methacrylate
- Pluronic F-127 nonionic surfactant
- Hematopoietic stem cells can also be prepared from cyst-like structures (also referred to as iPS-sac) obtained by culturing iPS cells.
- cyst-like structure also referred to as iPS-sac
- the "cyst-like structure” is a three-dimensional sac-like (with space inside) structure derived from iPS cells, which is formed by an endothelial cell population or the like and contains hematopoietic stem cells inside. be.
- the temperature conditions for culturing to produce hematopoietic stem cells from iPS cells are not particularly limited, but are, for example, about 37 ° C to about 42 ° C, preferably about 37 ° C to about 39 ° C. Further, the culture period can be appropriately determined by those skilled in the art while monitoring the number of hematopoietic stem cells and the like.
- the number of culture days is not particularly limited as long as hematopoietic stem cells can be obtained, but for example, at least 6 days or more, 7 days or more, 8 days or more, 9 days or more, 10 days or more, 11 days or more, 12 days or more, 13 days or more, Or 14 days or more, preferably 14 days.
- the long culture period is not a problem in the production of hematopoietic stem cells.
- the cells may be cultured under low oxygen conditions, and in one embodiment of the present invention, the low oxygen conditions include, for example, 15%, 10%, 9%, 8%, 7%, 6%, 5% or less. Oxygen concentration is mentioned.
- CD4 / CD8 double positive T cells are T cells that are both positive for surface antigens CD4 and CD8 (CD8 + CD4 + ), and T cells are positive for surface antigens CD3 and CD45.
- CD4 / CD8 double positive T cells can be identified as cells positive for CD4, CD8, CD3 and CD45.
- CD4 / CD8 double positive T cells can be induced to differentiate into CD4 single positive cells or CD8 single positive cells.
- CD4 / CD8 double positive T cells can be produced by a method comprising culturing hematopoietic stem cells in a culture medium supplemented with a p38 inhibitor and / or SDF-1.
- P38 inhibitor is defined as a substance that inhibits the function of p38 protein (p38MAP kinase).
- p38 inhibitors include, but are not limited to, chemical inhibitors of p38, dominant negative variants of p38, or nucleic acids encoding them.
- Chemical inhibitors of p38 include SB203580 (4- (4-fluorophenyl) -2- (4-methylsulfonylphenyl) -5- (4-pyridyl) -1H-imidazole) and its derivatives, SB202190 (4-).
- the p38 inhibitor is added to the culture medium, for example, in the range of about 1 ⁇ M to about 50 ⁇ M.
- Dominant negative variants of p38 include p38T180A, which is a point mutation of threonine at position 180 located in the DNA binding region of p38 to alanine, and p38Y182F, which is a point mutation of tyrosine at position 182 of p38 to phenylalanine in humans and mice. Can be mentioned.
- SDF-1 (Stromal cell-derived factor 1) is not only SDF-1 ⁇ or its mature form, but also isoforms such as SDF-1 ⁇ , SDF-1 ⁇ , SDF-1 ⁇ , SDF-1 ⁇ or SDF-1 ⁇ , or them. It may be a mature form of the above, or it may be a mixture of any proportions thereof and the like. Preferably SDF-1 ⁇ is used. SDF-1 may also be referred to as CXCL-12 or PBSF.
- SDF-1 may be substituted, deleted and / or added with one or several amino acids in its amino acid sequence as long as it has activity as a chemokine, and similarly, sugar chains may be substituted or deleted. And / or may be added.
- SDF-1 may be of a mammal, eg, a non-human mammal such as a monkey, sheep, cow, horse, pig, dog, cat, rabbit, rat, or mouse.
- GenBank registration number: NP_954637 can be used as human SDF-1 ⁇
- a protein registered with GenBank registration number: NP_000600 can be used as SDF-1 ⁇ .
- SDF-1 a commercially available product may be used, a product purified from nature may be used, or a product manufactured by peptide synthesis or a genetic engineering method may be used. SDF-1 is added to the culture medium, for example, in the range of about 10 ng / mL to about 100 ng / mL.
- the culture medium used for producing the CD4 / CD8 double positive T cells is not particularly limited, but the culture medium used for culturing animal cells is used as the basal culture medium, and p38 inhibitor and / or SDF-1 is more preferable. It can be prepared by adding vitamin Cs.
- the types of vitamin C used in the production of CD4 / CD8 double positive T cells are as described above, for example, and the concentration of vitamin C is, for example, 5 to 200 ⁇ g / mL.
- basal culture medium examples include Isove's Modified Dulbecco's Medium (IMDM) culture medium, Medium 199 culture medium, Eagle's Minimum Essential Medium (EMEM) culture medium, ⁇ MEM culture medium, Dulbecco's modified Eagle's Medium (DMEM) culture medium, and Ham. , RPMI 1640 culture medium, Fischer's Neurobasal Medium culture solution (Life Technologies), and a mixed culture solution thereof. Serum may be added to the culture broth, or serum-free.
- IMDM Isove's Modified Dulbecco's Medium
- EMEM Eagle's Minimum Essential Medium
- DMEM Dulbecco's modified Eagle's Medium
- Ham Ham.
- RPMI 1640 culture medium Fischer's Neurobasal Medium culture solution (Life Technologies), and a mixed culture solution thereof. Serum may be added to the culture broth, or serum-free.
- basal culture solutions include, for example, albumin, insulin, transferase, selenium, fatty acids, trace elements, 2-mercaptoethanol, thiolglycerols, lipids, amino acids, L-glutamine, non-essential amino acids, vitamins, growth factors. , Low molecular weight compounds, antibiotics, antioxidants, pyruvate, buffers, inorganic salts, and one or more substances selected from cytokines and the like.
- Cytokines selected from the group consisting of SCF, TPO (thrombopoietin), FLT3L and IL-7 may be further added to the culture medium used for producing CD4 / CD8 double positive T cells. These concentrations are, for example, 10-100 ng / mL for SCF, 1O-200 ng / mL for TPO, 1-100 ng / mL for FLT3L, and 1-100 ng / mL for IL-7. Is.
- Hematopoietic stem cells may be adherently cultured or suspension-cultured, but adherent culture is preferable.
- the culture vessel may be coated and used.
- Matrigel Niwa A, et al. PLoS One. 6 (7): e22261, 2011
- collagen gelatin
- laminin heparan sulfate proteoglycan
- retronectin Fc-DLL4 or entactin
- the culture temperature conditions for culturing hematopoietic stem cells for producing CD4 / CD8 double positive T cells are not particularly limited, but are preferably about 37 ° C to about 42 ° C, preferably about 37 ° C to about 39 ° C, for example. Is more preferable. Further, the culture period can be appropriately determined by those skilled in the art while monitoring the number of CD4 / CD8 double positive T cells and the like. As long as CD4 / CD8 double positive T cells can be obtained, the number of culture days is not particularly limited, but for example, at least 10 days or more, 12 days or more, 14 days or more, 16 days or more, 18 days or more, 20 days or more, 22 days or more. , Or 23 days or more, preferably 23 days.
- the obtained CD4 / CD8 double positive T cells may be isolated and used, or may be used as a cell population containing other cell types.
- isolation methods well known to those of skill in the art can be used. For example, a method of labeling with an antibody against CD4, CD8, CD3 and / or CD45 and isolation using a flow cytometer, or a method of purification using an affinity column on which a desired antigen is immobilized can be mentioned.
- CD8 single positive T cells that is, mature T cells, are cells (CD8 + CD4- ) positive for the surface antigen CD8 among T cells, and are also called cytotoxic T cells. Since T cells can be recognized by being positive for the surface antigens CD3 and CD45, CD8 single positive T cells can be identified as cells positive for CD8, CD3 and CD45 and negative for CD4. ..
- CD8 single positive T cells can be produced by a method including a step of culturing CD4 / CD8 double positive T cells in a culture medium supplemented with a corticohormonal agent.
- the corticosteroid agent is preferably a glucocorticoid or a derivative thereof, and examples thereof include cortisone acetate, hydrocortisone, fludrocortisone acetate, prednisolone, triamcinolone, methylprednisolone, dexamethasone, betamethasone, or beclomethasone propionate.
- the corticosteroid agent is dexamethasone. Its concentration in the culture medium is, for example, 1 to 100 nM.
- the culture medium used for producing CD8 single positive T cells is not particularly limited, but can be prepared by using the culture medium used for culturing animal cells as the basal culture medium and adding an corticohormonal agent to it.
- the basal culture medium include Isove's Modified Dulbecco's Medium (IMDM) culture medium, Medium 199 culture medium, Eagle's Minimum Essential Medium (EMEM) culture medium, ⁇ MEM culture medium, Dulbecco's modified Eagle's Medium (DMEM) culture medium, and H12 culture medium.
- IMDM Isove's Modified Dulbecco's Medium
- EMEM Eagle's Minimum Essential Medium
- DMEM Dulbecco's modified Eagle's Medium
- H12 culture medium examples thereof include a solution, RPMI 1640 culture solution, Fischer's Neurobasal Medium culture solution (Life Technologies), and a mixed culture solution thereof.
- Serum may be added to the culture broth, or serum-free.
- the basal culture medium may be, for example, albumin, insulin, transferase, selenium, fatty acid, trace elements, 2-mercaptoethanol, thiolglycerol, monothiolglycerol, lipid, amino acid, L-glutamine, non-essential amino acids, It may also contain one or more substances selected from vitamins, growth factors, low molecular weight compounds, antibiotics, antioxidants, pyruvate, buffers, inorganic salts, cytokines and the like.
- the culture medium used for producing CD8 single positive T cells preferably further contains anti-CD3 antibodies, vitamin Cs, or cytokines.
- cytokine examples include IL-2, IL-7, IL-15, IL-21 and the like.
- the anti-CD3 antibody is not particularly limited as long as it is an antibody that specifically recognizes CD3, and examples thereof include an antibody produced from an OKT3 clone.
- the concentration of the anti-CD3 antibody in the culture medium is, for example, 10 to 1000 ng / mL.
- the vitamin Cs used for producing CD8 single positive T cells are, for example, those described above, and can be used under the same conditions as described above.
- the concentration of cytokines used for the production of CD8 single positive T cells in the culture medium is, for example, 10 to 1000 U / mL for IL-2 and 1 to 100 ng / mL for IL-7.
- the temperature conditions for culturing CD4 / CD8 double positive T cells for producing CD8 single positive T cells are not particularly limited, but are preferably about 37 ° C to about 42 ° C, preferably about 37 ° C to about 38 ° C, for example. About ° C is more preferable.
- the culture period can be appropriately determined by those skilled in the art while monitoring the number of CD8 single positive T cells and the like. As long as CD8 single positive T cells can be obtained, the number of culture days is not particularly limited, but is, for example, at least 1 day or more, 2 days or more, 3 days or more, 4 days or more, or 5 days or more, preferably 3 days. ..
- the cDNA encoding the TCR ⁇ chain and the ⁇ chain for each single cell.
- the T cells collected from the subjects are a population of T cells with genetic diversity as a whole, but were identified as CD106-positive T cells without determining the antigen or peptide sequence recognized by the TCR of each individual T cell.
- the antigen specificity of individual T cells is different. It is preferable to prepare the cDNA for each single cell in order to select the TCR that is optimal for each tumor-related antigen, that is, highly responsive to each tumor-related antigen.
- a T cell population that responds to a tumor-related antigen may be isolated as a single cell by a cell sorter or the like using CD106 as a marker.
- cell surface CD137 may be used as a marker for isolating cells.
- Known techniques for isolating human T cells include, for example, flow cytometry using antibodies against T cell surface markers such as CD106, CD3 and CD137 and cell sorters.
- Gene cloning can be performed from the obtained single T cells using the PCR method to amplify the cDNAs encoding the TCR ⁇ chain and ⁇ chain, respectively.
- PCR fragments amplified using the isolated TCR cDNA as a template can be incorporated into viral or non-viral vectors using, for example, the Gibson assembly system.
- a gene in which an isolated TCR ⁇ chain gene and a TCR ⁇ chain gene are linked via a T2A sequence is bound to the downstream of the ubiquitin promoter, and further downstream to the IRES (internal ribosome entry site) sequence.
- a marker gene such as EGFR (EGFRt, truncated EGFR) excluding the ligand binding site and the intracellular domain or CD19 lacking the intracellular domain is ligated, and this construct is integrated into a viral vector or a non-viral vector.
- a viral vector and a non-viral vector can be used, but a non-viral vector is preferable.
- a transposon vector is preferable, and a piggyBac® transposon vector is further preferable.
- the transposon method is a next-generation gene transfer method that is cheaper and safer than the conventional viral vector method.
- a method for introducing a cDNA pair encoding a TCR ⁇ chain and a ⁇ chain into the mature T cell differentiated from a T cell a method using a viral vector, a method using a non-viral vector, or replacement of TCR using a genome editing technique is used. Any of these can be adopted.
- virus vector examples include viral vectors such as lentivirus, retrovirus, adenovirus, adeno-associated virus, herpes virus and Sendai virus, and animal cell expression plasmids, with retrovirus or lentivirus being preferred.
- viral vectors such as lentivirus, retrovirus, adenovirus, adeno-associated virus, herpes virus and Sendai virus, and animal cell expression plasmids, with retrovirus or lentivirus being preferred.
- a spin infection method or the like When a non-viral vector is used, the transposon method is preferable.
- the CRISPR / Cas9 method, the CRISPR / MAD method and the CRISPR / CAS3 method may be used to replace the TCR using the genome editing technique.
- Examples of the method for introducing a gene of a non-viral vector or the method for introducing a guide RNA and donor DNA for genome editing include a lipofection method, a liposome method, a calcium phosphate co-precipitation method, a DEAE dextran method, a microinjection method and an electroporation method. .. PCR products can also be introduced directly into cells without the use of vectors. It is preferable to use an electroporation method for cell transfer of a transposon vector or PCR product. As the electroporation device, the gene transfer device ExPERT® system (MaxCyte) is preferable.
- Genome editing techniques such as CRISPR / Cas9 and TALEN may be used as a method for introducing cDNA pairs encoding the TCR ⁇ chain and ⁇ chain, respectively.
- the introduction of the TCR gene by CRISPR / Cas9 is, for example, homologous to an endogenous TCR ⁇ chain and a guide RNA designed in the gene for the ⁇ chain (guide RNA to the sense strand and guide RNA to the antisense strand), as well as the endogenous TCR ⁇ strand.
- the promoter used in the expression vector used when introducing the cDNA pair into the cell examples include EF1 ⁇ promoter, SR ⁇ promoter, SV40 promoter, LTR promoter, CMV promoter, RSV promoter, HSV-TK promoter, ubiquitin promoter and the like. Can be mentioned. These promoters may be capable of controlling the expression of the gene inserted downstream of the promoter depending on the presence or absence of a drug such as tetracycline.
- the expression vector can include an enhancer, a poly A addition signal, a selectable marker gene (for example, a neomycin resistance gene), an SV40 origin of replication, and the like.
- the iPS cell clone into which the cDNA pair has been introduced, the hematopoietic stem cell differentiated from the iPS cell clone, the immature T cell differentiated from the hematopoietic stem cell, or the mature T cell differentiated from the immature T cell is the above-mentioned culture medium.
- culture conditions such as culture solution composition and culture temperature, regenerated T cells expressing TCR consisting of ⁇ -chain and ⁇ -chain encoded by the cDNA pair can be obtained.
- feeder cells are preferably autologous or allogeneic peripheral blood mononuclear cells.
- Autologous means that the subject from which the peripheral blood mononuclear cells and the iPS cell clone are derived is the same, and “allogeneic” means that the peripheral blood mononuclear cells and the iPS cell clone are derived from. It means that the subjects who do this are different.
- the iPS cell into which the cDNA pair has been introduced, the hematopoietic stem cell, the immature T cell, or the mature T cell may be cloned.
- a colony pickup method for cloning it is preferable to perform a colony pickup method for cloning.
- the colony pickup method is not particularly limited, and examples thereof include a method using a pipette man under a microscope, a limiting dilution method, and a method using a fully automated colony picker.
- TCRV ⁇ analysis kit BECKMAN COULTER: Catalog No. IM-3497. Since marker genes such as EGFRt (truncated EGFR) and CD19t (truncated CD19) are incorporated into the vector, the expression of TCR ⁇ chain and ⁇ chain can be inferred by analyzing the expression of the marker gene.
- the iPS cell clone, the hematopoietic stem cell, the immature T cell or the mature T cell may form a master cell bank after expansion culture.
- master cell bank means that the iPS cell clone, the hematopoietic stem cell, the immature T cell or the mature T cell is dispensed into a separate cell storage container for each single pool of a single clone. It is an accumulation. Usually, it is preferable to proliferate the cells within a range that does not change the properties of the cells and dispense them into a plurality of cell storage containers.
- the cells stored in the master cell bank are cells into which a TCR gene or CAR (chimeric antigen receptor) gene is introduced and used as a starting material for producing regenerated T cells, and are mastered for each production of the regenerated T cells.
- a cell storage container containing the required number of the cells can be taken out from the cell bank. Therefore, the regenerated T cells of the present invention can be repeatedly supplied with the same quality.
- a master cell bank it is preferable to cryopreserve the cells dispensed into the cell storage container.
- Methods of cryopreserving cells are well known to those of skill in the art. For example, a single clone of expanded-cultured cells is collected, washed with a buffer or culture medium, the number of cells is counted, concentrated by centrifugation or the like, and frozen medium (for example, a culture medium containing 10% DMSO). After suspending in, it can be cryopreserved at low temperature.
- a master cell bank can be constructed by accumulating 200 to 1000 cell storage containers containing 1 ⁇ 10 6 to 10 7 cells per cell in a cell storage container stocker or the like.
- the master cell bank of the present invention can be stored in any facility or storage that can be cryopreserved.
- the storage temperature is not particularly limited as long as it is a temperature suitable for storing cells.
- ⁇ 20 ° C., ⁇ 80 ° C. and ⁇ 120 to -196 ° C. are mentioned, but ⁇ 150 ° C. or lower is preferable.
- the number of TCR pairs corresponding to tumor-related antigens is said to be 5 to 10 per epitope, and each TCR pair is predicted to have different susceptibility to point mutant variants of tumor-related antigens. There is. Therefore, for example, even when a point mutation occurs in a tumor-related antigen, there is a high possibility that there is a TCR capable of recognizing the epitope, and preparation of antigen-specific regenerated T cells for the point mutation variant is also possible. Can be done quickly.
- TCRs that respond to those tumor-related antigens can be started from already acquired iPS cells having high differentiation potential into T cells or differentiated cells derived from iPS cells, it is possible to rapidly produce regenerated T cells. Is possible.
- T cells from the TCR acquisition source The T cells that are the source of the TCR pair corresponding to the tumor-related antigen are preferably collected from the tumor tissue.
- the collected T cells may be isolated using CD106 as a marker after amplifying a tumor-responsive cell population by co-culture with tumor tissue in vitro.
- T cells for obtaining a TCR pair can be collected in advance at any time independently of the treatment time of the regenerated T cell replacement therapy, the regenerated T cell replacement therapy can be started promptly. ..
- the obtained TCR pair is the subject to be treated. It is necessary to confirm that it does not show an allo reaction to cells.
- the method of confirmation is a known method. For example, it can be confirmed by mixed lymphocyte culture (MLR) or the like that the obtained T cells having the TCR pair do not respond to the cells of the subject to be treated. Alternatively, it is confirmed that the T cells having the obtained TCR pair do not respond to the antigen in which one or more residues of the constituent amino acids of the antigen are replaced with other amino acids.
- MLR mixed lymphocyte culture
- the pharmaceutical composition containing the regenerated T cells of the present invention can be used for treating a cancer treatment target.
- the pharmaceutical composition of the present invention can be produced by a method commonly used in the field of pharmaceutical technology, for example, the method described in the Japanese Pharmacopoeia.
- the pharmaceutical composition of the present invention may contain a pharmaceutically acceptable additive. Examples of the additive include a cell culture solution, a physiological saline solution, an appropriate buffer solution (for example, a phosphoric acid-based buffer solution), and the like.
- the pharmaceutical composition of the present invention can be produced by suspending regenerated T cells in physiological saline, an appropriate buffer solution (for example, a phosphate-based buffer solution), or the like. It is preferable to contain, for example, 1 ⁇ 10 7 or more cells as a single dose so that the desired therapeutic effect is exhibited. A more preferable cell content is 1 ⁇ 10 8 or more, and even more preferably 1 ⁇ 10 9 or more. The cell content can be appropriately adjusted in consideration of the sex, age, body weight, condition of the affected area, cell condition, etc. of the administration subject.
- the pharmaceutical composition of the present invention may contain dimethyl sulfoxide (DMSO), serum albumin and the like for the purpose of protecting the cells.
- DMSO dimethyl sulfoxide
- antibiotics and the like may be contained, and vitamins and cytokines may be contained for the purpose of promoting cell activation and differentiation.
- the pharmaceutical composition of the present invention contains other components (eg, carriers, excipients, disintegrants, buffers, emulsifiers, suspensions, soothing agents, stabilizers, preservatives, preservatives) that are acceptable for the formulation. , Physiological saline, etc.) may be contained.
- the pharmaceutical composition containing the regenerated T cells of the present invention as an active ingredient can be cryopreserved.
- the storage temperature is not particularly limited as long as it is a temperature suitable for storing cells.
- ⁇ 20 ° C., ⁇ 80 ° C. and ⁇ 120 to -196 ° C. are mentioned, but ⁇ 150 ° C. or lower is preferable.
- cells are preferably stored in suitable containers such as freezing vials and freezing bags. Procedures for minimizing the risk of cell damage during freezing and thawing of regenerated T cells are well known to those of skill in the art.
- the T cells are recovered from the culture medium, washed with a buffer solution or a culture solution, the number of cells is counted, and then concentrated by centrifugation or the like to be concentrated in a frozen medium (for example, for example). After suspending in a culture medium containing 10% DMSO), it is cryopreserved at low temperature.
- Regenerated T cells may be stored as individual clones or as a mixture of each clone.
- the pharmaceutical composition containing the regenerated T cells of the present invention contains, for example, 5 ⁇ 10 4 to 9 ⁇ 10 10 regenerated T cells per container such as a freezing vial and a freezing bag, but for the cancer of interest. It can be changed according to the type, administration target, administration route, and the like.
- Examples of the route of administration of the pharmaceutical composition containing the regenerated T cells of the present invention include infusion, intratumoral injection, intraarterial injection, portal vein injection, intraperitoneal administration and the like.
- the route of administration is not limited to these as long as the regenerated T cells, which are the active ingredients in the pharmaceutical composition of the present invention, are delivered to the affected area.
- the administration schedule may be a single dose or multiple doses. As the period of the multiple administration, for example, a method of repeating the administration once every 2 to 4 weeks, a method of repeating the administration once every 6 months to 1 year, and the like can be adopted.
- the gender, age, body weight, pathological condition, etc. of the target patient can be taken into consideration.
- the pharmaceutical composition containing the regenerated T cells of the present invention is used for the prevention or treatment of cancer in a cancer patient, if the TCR on the regenerated T cells is allogeneic, the allo in the body of the cancer patient.
- a pharmaceutical composition containing regenerated T cells introduced with TCR that does not show an allo reaction to normal cells of a cancer patient is used.
- the pharmaceutical composition of the present invention is used for the prevention or treatment of cancer.
- Cancers include hepatocellular carcinoma, hepatoblastoma, gastric cancer, esophageal cancer, lung cancer, pancreatic cancer, renal cell carcinoma, breast cancer, ovarian cancer, skin cancer such as malignant melanoma, bladder cancer, Head and neck cancer, uterine cancer, cervical cancer, glioblastoma, prostate cancer, neuroblast tumor, chronic lymphocytic leukemia, papillary thyroid cancer, colon cancer, brain tumor, sarcoma and B-cell non-hodgkin lymphoma
- cancers include hepatocellular carcinoma, hepatoblastoma, gastric cancer, esophageal cancer, lung cancer, pancreatic cancer, renal cell carcinoma, breast cancer, ovarian cancer, skin cancer such as malignant melanoma, bladder cancer, Head and neck cancer, uterine cancer, cervical cancer, glioblastoma, prostate cancer, neuroblast tumor, chronic lympho
- the pharmaceutical composition of the present invention can be suitably used for highly immunogenic cancers such as hepatocellular carcinoma, hepatoblastoma, colon cancer, lung cancer and malignant melanoma.
- Highly immunogenic cancer is a cancer that has a high ability to induce an immune response, and many gene mutations are found in cancer cells (1000 or more per cell or 5000 or more), including T cells. It refers to cancer that is recognized by the immune cells, the immune checkpoint inhibitor is effective, and the tumor tissue is heavily infiltrated with many immune cells (many immune cells are found by histopathological staining).
- FIG. 1 shows a manufacturing process of regenerated T cells of the present invention.
- Mononuclear cells in the tumor tissue of a cancer patient (subject) being treated are collected, T cells that specifically react with the tumor antigen are isolated as CD106-positive T cells, and the TCR gene is isolated from the CD106-positive T cells.
- Fig. 1- (2') A TCR gene that is expected to have a higher therapeutic effect than the TCR binding ability encoded by the TCR gene to a tumor was selected (FIG. 1- (3')).
- TCR repertoire TCR repertoire
- iPS cells were produced from non-T non-B cells or monocytes in the peripheral blood of the patient (FIGS. 1- (1) and (2)).
- iPS cell clones having good differentiation efficiency from the obtained iPS cells to T cells were selected (Fig. 1- (3)). By this selection, it was confirmed that the variation in the induction efficiency to T cells due to the difference in iPS cell clones was remarkably reduced, and the robustness and efficiency of the production of regenerated T cells were improved.
- the above-mentioned selected TCR gene group that reacts specifically with a tumor antigen is expressed in the iPS cell clone having good differentiation efficiency into T cells (Fig. 1- (4)), and each selected TCR gene is expressed. Differentiated and proliferated into mature T cells (Fig. 1- (5)).
- the mature T cells are tumor antigen-specific cytotoxic T cells and are regenerated T cells. These regenerated T cells are administered to cancer patients (Fig. 1- (6)).
- a step of producing iPS cells (FIGS. 1- (1) to (3)) and a step of acquiring a TCR gene that reacts with a tumor antigen (FIGS. 1- (2') and (3')). Since these steps can be performed in parallel, these steps can be completed in a shorter period (about 55 days) as compared with the case where these steps are sequentially performed.
- Tumor antigen-specific TCR genes were isolated and antigen-specific reactivity was verified as follows (see the upper partial diagram of FIG. 2). After co-culturing a tumor (specimen) isolated from a cancer patient (subject) with CD8-positive cytotoxic T cells, CD106-positive cytotoxic T cells activated by a cell sorter (CD8-positive) And CD106-positive cells) were single-cell sorted (Fig. 2- (2)). TCR gene pairs (TCR ⁇ chain gene and TCR ⁇ chain gene) are isolated from isolated single cells by single cell PCR, sequence analysis is performed on the isolated TCR gene pairs, and tumor-reactive T cell types (TCR). Repatoa) and its frequency of appearance were analyzed (Fig. 2- (3)).
- the isolated TCR gene pair was expressed in a TCR gene-deficient T cell line incorporating a reporter gene to reconstruct the TCR gene complex (Fig. 2- (4)). Subsequently, the reactivity (antigen-specific reactivity) between the reconstructed TCR gene complex and the tumor was verified (Fig. 2- (5)). That is, the T cell line expressing the TCR gene pair and the target tumor cell are co-cultured, but when the expressed TCR and the tumor are antigen-specifically bound, the TCR gene signal is activated and targeted. A reporter gene integrated downstream of the gene promoter is expressed. Then, the reporter gene activity was measured, and the antigen-specific reactivity was verified by evaluating the binding of the tumor antigen-specific TCR.
- TCR gene pairs showing tumor-specific reactivity are selected with high frequency of appearance, and non-T non-B cells or monocyte-derived iPS cells (M-iPS) described later are selected. It was used as a transgene to cells).
- TCR gene-introduced iPS cells and regenerated T cells was performed as follows (see the lower partial view of FIG. 2).
- IPS cells were prepared from peripheral blood mononuclear cells of cancer patients (Fig. 2- (2')).
- the M-iPS cells described in the figure are iPS cells that are not derived from T cells, and are cells that have not undergone gene rearrangement of the TCR gene.
- M-iPS cell lines having good differentiation efficiency into T cells were selected (FIG. 2- (3')).
- a tumor-specific TCR gene (both TCR ⁇ chain gene and TCR ⁇ chain gene, see FIG. 2- (3)) was introduced into the selected M-iPS cell line using a transposon vector (FIG. 2).
- TCR-iPS cell line was selected.
- hematopoietic stem progenitor cells were induced using the embryoid body method, and differentiation was induced into mature T cells via immature T cells by a stepwise differentiation induction method that mimics T cell development in vivo. ..
- FIG. 4 shows the analysis results of the regenerated T cells using the cell surface antigen marker by the flow cytometer.
- the expression of CD45 + TCR ⁇ + CD3 + CD4 - CD8 ⁇ + which is observed in mature cytotoxic T cells in vivo, was confirmed in the regenerated T cells derived from iPS cells.
- FIG. 5 shows the results of analysis of telomeres (index of rejuvenation), which is a cell senescence marker, for regenerated T cells mediated by iPS cells of the present invention.
- telomeres index of rejuvenation
- A peripheral blood mononuclear cells
- B tumor antigen-specific T cells
- C iPS cells
- D tumor antigen-specific regenerated T cells
- regenerated T cells mediated by iPS cells of the present invention For regenerated T cells mediated by iPS cells of the present invention, the expression of PD-1 and TIGIT molecules, which are one of the cell exhaustion markers related to immune checkpoints, was stained with anti-TIGIT antibody and anti-PD-1 antibody, and flow cytometer was used. was analyzed by. For comparison, pre-regeneration tumor antigen-specific T cells were also analyzed. The results are shown in FIG. It was confirmed that the regenerated T cells of the present invention had significantly reduced expression of PD-1 and TIGIT molecules as compared with the tumor antigen-specific T cells before regeneration. Therefore, it is suggested that the regenerated T cells of the present invention have high cytotoxic activity.
- Cytotoxic T cells CD8 ⁇ chain / ⁇ chain double positive cells
- regenerated T cells of the present invention in peripheral blood mononuclear cells collected from healthy subjects were used as PMA (Phorbol 12-Myristate 13-Acetate) and ionomycin (Ionomycin).
- PMA Phorbol 12-Myristate 13-Acetate
- Ionomycin ionomycin Stimulated and produced IL-2 and IFN- ⁇ amounts were compared. The results are shown in FIG. It was confirmed that the number of cells producing IL-2 and IFN ⁇ was significantly increased in the regenerated T cells of the present invention as compared with the cytotoxic T cells obtained from healthy subjects.
- Mononuclear cells were isolated from peripheral blood collected from patients with hepatocellular carcinoma or hepatoblastoma using a mononuclear cell separation solution Lymphoprep®. From the obtained mononuclear cells, CD19 / CD20-positive B cells and CD3 / CD4 / CD8-positive T cells were removed using FACS or MACS beads to obtain non-T non-B cells or monocytes.
- Sendai virus (CytoTune® 2.0) and SV40Tag-encoded Sendai virus (CytoTune® 2.0) carrying Yamanaka 4 factors (Oct3 / 4, Sox2, Klf4 and c-Myc) in the obtained non-T non-B cell or monocyte cell population.
- the virus was infected with a MOI (multiplicity of infection) of 5 to 20.
- the SV40 may be excluded.
- the obtained iPS cells consist of a large number of iPS cell clones. Therefore, a colony pick was performed and cloned. All cloned iPS cells were cryopreserved. The cloned iPS cells were cultured in a differentiation medium for about 10 days to induce hematopoietic stem cells, and CD34 / CD43 double positive hematopoietic stem cells were isolated. The isolated hematopoietic stem cells were cultured for about 21 days on a plate coated with FcDLL4, which is a fusion protein of the DLL4 protein and the Fc region of immunoglobulin, to induce differentiation into T cells.
- FcDLL4 is a fusion protein of the DLL4 protein and the Fc region of immunoglobulin
- the frequency of immature cytotoxic T cells obtained after culturing for the above 21 days was verified by the CD8 ⁇ chain / ⁇ chain double positive rate, and the clone with the highest frequency of appearance of CD8 ⁇ chain / ⁇ chain double positive cells was selected.
- iPS cell clones with good differentiation efficiency into T cells are expanded and cultured in iPS cell maintenance medium for 2 weeks, then dispensed into a cell storage container and cryopreserved to construct a master cell bank. did.
- T cell receptor ⁇ -chain and ⁇ -chain with confirmed tumor antigen specificity for iPS cell clones derived from non-T non-B cells or monocytes with good differentiation efficiency into T cells obtained in Example 2.
- a piggyBac® transposon vector having the gene encoding the above was introduced using the electroporation method.
- iPS cells expressing the target T cell receptor ⁇ chain and ⁇ chain were isolated by a cell sorter using the expression of the marker molecule CD19 as an index.
- the isolated iPS cells were cultured in a differentiation medium for about 10 days to induce CD34 / CD43 double-positive hematopoietic stem cells, and isolated by a cell sorter.
- the isolated blood stem cells were cultured on a plate coated with FcDLL4 for about 21 days to induce differentiation into T cells.
- Immature T cells with double positive CD8 ⁇ chain / ⁇ chain obtained after the above 21-day culture were isolated and purified using a cell sorter. Immature T cells were then co-located as PHA (phytohemagglutinin) and feeder cells in the presence of peripheral blood mononuclear cells, in the presence of Retronectin® and anti-CD3 antibody, or in the presence of anti-CD3 and anti-CD28 antibodies. It was cultured and induced into mature cytotoxic T cells. These stimuli were given more than once. The performance of the obtained T cells was confirmed by the cytotoxic activity, IFN- ⁇ production and antigen-binding ability of GPC3-specific target cells.
- PHA phytohemagglutinin
- Tumor tissues were obtained from surgical specimens before the start of treatment with anti-PD-1 antibody in melanoma patients for whom anti-PD-1 antibody was significantly effective. Collagenase and DNase were added to the obtained tumor tissue, and the cells were separated by enzymatic treatment by stirring at 37 ° C. for 30 minutes. From a cell mixture of tumor tissue-derived cells and tumor-infiltrating immune cells, CD3-positive cells were sorted using a BD FACSAria III® cell sorter (BD Biosciences) to obtain cells expressing TCR. rice field.
- BD FACSAria III® cell sorter BD Biosciences
- T cells For each of the obtained T cells, a single sequence was used for both the gene expression of the marker candidate and the TCR sequence using the Chromium system (10X Genomics) 5-prime kit and V (D) J enrichment kit. Cell gene expression analysis was performed. HiSeq3000 (Illumina) was used as the sequencer.
- Fig. 8 The results are shown in Fig. 8.
- cells positive for the expression of the marker described in the panel are shown colored.
- the cells are clustered according to the expression pattern, and the circled part corresponds to the tumor-damaging T cell.
- CD106 VCAM1 positive cells are highly specific to the tumor-damaging T cell population. It is shown that CD106 can be used as a selectable marker for tumor-damaging T cells with higher specificity than surface markers other than CD106.
- the TCR sequence was obtained in cells having a ⁇ chain of 90% or more and cells having an ⁇ chain of 60 to 90%.
- T cells of tumor tissue were separated, CD3-positive cells were sorted from the obtained cell mixture using BD FACSAria III, and T cells expressing TCR were designated as tumor-infiltrating T cells. Obtained.
- the tumor-infiltrating T cells and a cell line established from an autologous tumor as a stimulant were co-cultured, and IFN- ⁇ production was compared with the case of no stimulation. IFN- ⁇ production was measured by intracellular staining with an anti-IFN- ⁇ antibody.
- Cell staining was performed using anti-PD-1 antibody, anti-TIGIT antibody, anti-LAG3 antibody, and anti-CD106 antibody. As a negative control, an isotype control antibody against the anti-CD106 antibody was used.
- IFN- ⁇ is produced by stimulation with the autotumor cell line, and in the marker-positive cell subpopulation other than CD106, IFN- ⁇ is produced by autotumor stimulation, but the marker. Since IFN- ⁇ is also produced in the negative cell subpopulation, it can be understood that the specificity is inferior to that of CD106.
- TCR gene into mature T cells differentiated from iPS cell clones From the non-T non-B cell or monocyte-derived iPS cell clones obtained in Example 2 having good differentiation efficiency into T cells, to mature T cells differentiated via hematopoietic stem cells and immature T cells.
- a gene (cDNA) encoding a GPC3 antigen-specific T cell receptor ⁇ -chain ⁇ -chain was introduced using the piggyBac® system in the same manner as in Example 3.
- FIG. 10 shows the results of analysis of the phenotype of mature T cells derived from gene-introduced iPS cells by a flow cytometer.
- “No EP” is the analysis result of the mature T cell used for gene transfer and expressing the WT1 antigen-specific T cell receptor ⁇ chain ⁇ chain; “EGFP”.
- EGFP enhanced green fluorescent protein
- TCR-CD19 is a GPC3 antigen-specific T cell receptor ⁇ -chain ⁇ -chain gene and intracellular.
- the analysis result of the mature T cell which introduced the piggyBac® transposon vector in which the defective human CD19 gene was integrated into the tandem is shown.
- GPC3 antigen specificity In mature T cells derived from iPS cells represented by "TCR-CD19", in addition to the expression of the CD3 gene and the intracellular defective human CD19 gene, which is a tracer gene integrated into the piggyBac® transposon vector, GPC3 antigen specificity. Binding to the GPC3 peptide / HLA complex (GPC3-Dex) recognized by the target T cell receptor ⁇ chain ⁇ chain was detected. That is, GPC3 antigen-specific T expressed on the cells by introducing the GPC3 antigen-specific T cell receptor ⁇ -chain ⁇ -chain gene into mature T cells derived from iPS cells using the piggyBac® system.
- the cell receptor ⁇ -chain ⁇ -chain functions as a molecule that recognizes the GPC3 peptide / HLA complex (GPC3-Dex). Therefore, a novel tumor-related antigen (neoantigen) and other tumor-related antigen-specific T cell receptor ⁇ -chain ⁇ -chain genes should be used as the T-cell receptor ⁇ -chain ⁇ -chain gene to be introduced into mature T cells derived from iPS cells. It was shown that mature T cells derived from iPS cells that recognize these antigens can be produced.
- FIG. 11 shows a method for selecting iPS cell clones having high efficiency of differentiation into T cells in the step of producing regenerated T cells from iPS cells reprogrammed with peripheral blood T cells.
- Mononuclear cells are isolated from the peripheral blood of subjects infected with EBV (Epstein-Barr virus), and the isolated mononuclear cells are stimulated with the EBV antigen in vitro to obtain a CD8-positive T cell population that recognizes the EBV antigen. Isolated.
- EBV Epstein-Barr virus
- Yamanaka 4 factors (Oct3 / 4, Sox2, Klf4 and c-Myc) and SV40T antigen were introduced into the isolated CD8-positive T cell population using a Sendai virus vector to obtain an iPS cell population.
- the iPS cell clones were separated from the obtained iPS cell population, the ability to differentiate into T cells was examined for each clone, and the iPS cell clones having high differentiation efficiency into T cells were selected.
- T cells that recognize the EBV antigen are cells that are unlikely to cause an allo reaction even when allogeneic transplantation is performed.
- iPS cell clones selected as cells having high differentiation efficiency into T cells, and regenerated T cells were performed.
- the method for producing cells is shown.
- the iPS cell clones derived from CD8-positive T cells that recognize EBV antigens and have high differentiation efficiency into T cells are ⁇ 2M genes and CIITA genes involved in the expression of MHC class I and MHC class II, and natural killer (NK) cells.
- the PVR gene involved in the activation of NK cells and the Rag2 gene involved in the rearrangement of T cell receptors were deleted using CRISPR / Cas9, while ⁇ 2 ⁇ / binding peptide / HLA, which is an inhibitory ligand for NK cells.
- the -E fusion gene (HLA-E * ) was expressed to obtain iPS cells that were not attacked by host T cells and NK cells.
- cells are expressed after in vivo administration by expressing a suicide gene such as drug-induced caspase-9 and / or a specific marker gene (EGFR (epidermal growth factor receptor), CD19, CD20, etc.). It can also be removed.
- the regenerated T cells differentiated and proliferated from iPS cells are host T cells for producing regenerated T cells for cancer treatment, and a master cell bank may be constructed from the host T cells.
- the host T cells can be used as a material for producing regenerated T cells into which a TCR gene or a CAR (chimeric antigen receptor) gene has been introduced. Since the host T cell is a T cell that recognizes an EBV antigen, it is unlikely to cause an allo reaction even if it is transferred into a living body.
- "Host T cells” are used as starting materials for the production of prophylactic or therapeutic agents for cancers containing regenerated T cells as an active ingredient, although the cells themselves are not used to treat patients. Means T cells.
- FIG. 13 shows a method for producing regenerated T cells that recognize cancer antigens from the host T cells.
- T cell receptor ⁇ chains that recognize reconstituted EBV antigens by gene replacement by genome editing using CRISPR / Cas9 and T cells that recognize cancer antigens, respectively. It was replaced with a T2a-mediated conjugate of the receptor ⁇ chain and the T cell receptor ⁇ chain.
- the T cell receptor ⁇ chain that recognizes the EBV antigen was removed by genome editing using CRISPR / Cas9.
- FIG. 13 it was possible to produce regenerated T cells that recognize cancer antigens.
- FIG. 14 collectively describes the methods shown in FIGS. 11 to 13.
- Regenerated T cells iPS-T cells
- iPS-T cells Regenerated T cells produced from the same type of universal iPS cells in which peripheral blood T cells have been reprogrammed can be used as a starting material for producing T cells into which a TCR gene or CAR gene has been introduced.
- Universal iPS cells have very low immunogenicity, so they do not cause rejection in patients with any type of MHC (Major Histocompatibility Complex). Means iPS cells that can be used. That is, iPS cells that can be administered to patients without considering MHC matching. Universal iPS cells can be produced by knocking out MHC class I or MHC class II molecules and expressing a ligand that suppresses NK cells.
- the viral vector used for the production of T cells used in conventional T cell replacement therapy or regeneration therapy may be used.
- iPS-T cells as a starting material, it becomes possible to produce desired T cells as an active ingredient of a preventive or therapeutic agent for cancer in a short period of time.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
〔1〕
(1)被験者から得られるT細胞であって、腫瘍関連抗原に対して反応性を有し、かつCD106陽性T細胞集団から、単一細胞ごとに、T細胞受容体α鎖およびβ鎖をそれぞれコードするcDNAを調製する工程、
(2)被験者の末梢血単核球であって、B細胞およびT細胞が除去された末梢血単核球またはT細胞をiPS細胞に初期化し、得られたiPS細胞からT細胞への分化効率が高いiPS細胞クローンを選別する工程、
(3)前記cDNAを、前記iPS細胞クローン、前記iPS細胞クローンから分化した造血幹細胞、前記造血幹細胞から分化した未熟T細胞または前記未熟T細胞から分化した成熟T細胞に導入する工程、および
(4)工程(3)において得られた、前記cDNAが導入された前記iPS細胞クローン、前記造血幹細胞または前記未熟T細胞の成熟T細胞への分化および前記成熟T細胞の増殖を行う工程、
を含む、iPS細胞を介する再生T細胞の製造方法。
〔2〕
工程(2)の実施が、工程(1)の実施に先行する、または工程(1)の実施と並行する、〔1〕に記載の方法。
〔3〕
工程(1)および(2)における被験者が、同一個体であって、がんの予防または治療対象である、〔1〕または〔2〕に記載の方法。
〔4〕
工程(1)および(2)における被験者が、互いに別個体であって、工程(2)における被験者が、がんの予防または治療対象である、〔1〕または〔2〕に記載の方法。
〔5〕
工程(1)および(2)における被験者が、互いに別個体であって、工程(1)における被験者が、がんの予防または治療対象である、〔1〕または〔2〕に記載の方法。
〔6〕
工程(1)および(2)における被験者が、同一個体または互いに別個体であって、工程(1)および(2)における被験者とは異なる被験者が、がんの予防または治療対象である、〔1〕または〔2〕に記載の方法。
〔7〕
さらに、工程(4)において得られる前記cDNAが導入されたT細胞から、がんの予防または治療対象である被験者に由来する細胞に対してアロ反応を示さないT細胞を選別する工程を含む、〔1〕または〔2〕に記載の方法。
〔8〕
さらに、工程(1)で調製されたcDNAから、がんの予防または治療対象である被験者に由来する細胞に対してアロ反応を誘導しないT細胞受容体をコードするcDNAを選別する工程を含む、〔1〕または〔2〕に記載の方法。
〔9〕
がんの予防または治療対象である被験者に由来する前記細胞が、末梢血単核球である、〔7〕または〔8〕に記載の方法。
〔10〕
工程(3)において、前記iPS細胞クローン、前記iPS細胞クローンから分化した前記造血幹細胞、前記造血幹細胞から分化した前記未熟T細胞または前記未熟T細胞から分化した前記成熟T細胞への前記cDNAの導入が、ウイルスベクターもしくは非ウイルスベクターを用いる、またはゲノム編集技術を用いる、〔1〕~〔9〕のいずれかに記載の方法。
〔11〕
前記ゲノム編集技術が、CRISPR/Cas9またはTALENである、〔10〕に記載の方法。
〔12〕
前記非ウイルスベクターが、トランスポゾンベクターである、〔10〕に記載の方法。
〔13〕
前記トランスポゾンベクターが、piggyBac(登録商標)トランスポゾンベクターである、〔12〕に記載の方法。
〔14〕
工程(4)において、前記cDNAが導入された前記iPS細胞クローン、前記造血幹細胞または前記未熟T細胞の成熟T細胞への分化および前記成熟T細胞の増殖を行う工程が、フィーダー細胞およびPHA(phytohemagglutinin)の存在下、レトロネクチン(登録商標)および抗CD3抗体の存在下、または抗CD3抗体および抗CD28抗体の存在下で行われる、〔1〕~〔13〕のいずれかに記載の方法。
〔15〕
前記フィーダー細胞が、自家または他家の末梢血単核球である、〔14〕に記載の方法。
〔16〕
工程(1)または(2)における前記被験者が、肝細胞がん、肝芽腫、胃がん、食道がん、肺がん、膵臓がん、腎細胞がん、乳がん、卵巣がん、悪性黒色腫などの皮膚がん、膀胱がん、頭頸部がん、子宮がん、子宮頸がん、膠芽腫、前立腺がん、神経芽腫瘍、慢性リンパ性白血病、甲状腺乳頭がん、大腸がん、脳腫瘍、肉腫またはB細胞非ホジキンリンパ腫の患者である、〔1〕~〔15〕のいずれかに記載の方法。
〔17〕
工程(1)または(2)における前記被験者が、免疫原性の高いがんの患者である、〔1〕~〔15〕のいずれかに記載の方法。
〔18〕
前記免疫原性の高いがんが、肝細胞がん、肝芽腫、大腸がん、肺がんまたは悪性黒色腫である、〔17〕に記載の方法。
〔19〕
工程(1)における前記T細胞集団が、CD3/CD106ダブルポジティブである、〔1〕~〔18〕のいずれかに記載の方法。
〔20〕
前記造血幹細胞が、CD34/CD43ダブルポジティブである、〔1〕~〔19〕のいずれかに記載の方法。
〔21〕
前記未熟T細胞が、CD8α鎖/β鎖ダブルポジティブである、〔1〕~〔20〕のいずれかに記載の方法。
〔22〕
工程(2)において選別された、T細胞への分化効率が高いiPS細胞クローン、または工程(3)における前記iPS細胞クローンから分化した造血幹細胞、前記造血幹細胞から分化した未熟T細胞または前記未熟T細胞から分化した成熟T細胞を保存し、マスターセルバンクを構成する、〔1〕~〔21〕のいずれかに記載の方法。
〔23〕
前記保存が凍結保存である、〔22〕に記載の方法。
〔24〕
前記マスターセルバンクに保存された前記iPS細胞クローン、前記造血幹細胞、前記未熟T細胞または前記成熟T細胞に対して、工程(3)および(4)を行う、〔22〕に記載の方法。
〔25〕前記iPS細胞クローン、前記造血幹細胞、前記未熟T細胞または前記成熟T細胞を含む、〔22〕に記載のマスターセルバンク。
〔26〕
〔1〕~〔24〕のいずれかに記載の方法により製造された再生T細胞。
〔27〕
〔26〕に記載の再生T細胞を含有する医薬組成物。
〔28〕
〔27〕に記載の医薬組成物を用いる、がんの予防または治療方法。
本発明において、被験者から得られる「T細胞」とは、細胞表面にT細胞受容体(T cell receptor:TCR)と呼ばれる抗原受容体を発現している細胞である。TCRには、α鎖およびβ鎖からなるヘテロ二量体と、γ鎖およびδ鎖からなるヘテロ二量体がある。α鎖およびβ鎖からなるTCRを有するT細胞は、αβ型T細胞と呼ばれ、またγ鎖およびδ鎖からなるTCRを有するT細胞は、γδ型T細胞と呼ばれる。本発明の一態様において、本発明のT細胞は、CD3/αβ型T細胞が好ましいが、CD3/γδ型T細胞であってもよい。本発明におけるT細胞のTCRは、遺伝子導入したものである。
本発明において、iPS細胞は、非T非B細胞もしくは単球またはT細胞を初期化して作製することが好ましいが、非T非B細胞もしくは単球またはT細胞に限定されるわけではない。「非T非B細胞」とは、T細胞として分類されず、かつB細胞とも分類されない単核球を意味する。本発明において、非T非B細胞または単球は、被験者の末梢血単核球として採取した後、単核球に含まれるT細胞およびB細胞を除去することにより調製することができる。末梢血単核球は、ヒト全血から単核球分離溶液により単離することができる。単核球分離溶液としては、例えばLymphoprep(登録商標)が挙げられる。単核球よりB細胞およびT細胞を除去するためには、B細胞の持つ表面抗原であるCD19、CD20、CD22またはB細胞受容体、およびT細胞の持つ表面抗原であるCD3、CD4またはCD8に対する抗体を利用して、例えばフローサイトメトリーまたはMACS(登録商標)ビーズなどの磁気ビーズを使用してもよい。T細胞は、ヒト全血から単核球分離溶液により単離することができる。単核球分離溶液としては、例えばLymphoprep(登録商標)が挙げられる。T細胞の精製は、T細胞の持つ表面抗原であるCD3、CD4もしくはCD8またはT細胞受容体を利用して行うことができるする。例えばフローサイトメトリーまたはMACS(登録商標)ビーズなどの磁気ビーズを使用してもよい。
造血幹細胞は、好ましくは、ビタミンC類を添加した培養液中でiPS細胞を培養することによって製造される。ここで、「ビタミンC類」とは、L-アスコルビン酸およびその誘導体を指し、「L-アスコルビン酸誘導体」とは、生体内で酵素反応によりビタミンCに変換されるものを意味する。L-アスコルビン酸の誘導体としては、例えば、リン酸ビタミンC、アスコルビン酸グルコシド、アスコルビルエチル、ビタミンCエステル、テトラヘキシルデカン酸アスコルビル、ステアリン酸アスコルビルおよびアスコルビン酸-2リン酸-6パルミチン酸が挙げられる。L-アスコルビン酸の誘導体は、好ましくは、リン酸ビタミンCであり、例えば、リン酸-Lアスコルビン酸ナトリウムまたはリン酸-L-アスコルビン酸マグネシウム等のリン酸-Lアスコルビン酸塩が挙げられる。ビタミンC類は、例えば、培養液において、5~500μg/mLの濃度で含有される。
本発明において、TCRα鎖およびβ鎖をそれぞれコードするcDNAの調製は、単一細胞ごとに行うことが好ましい。被験者から採取されるT細胞は、全体として遺伝的多様性を有するT細胞集団であるが、個々のT細胞が有するTCRが認識する抗原またはペプチド配列が決定されないままCD106陽性T細胞として同定されたものであり、個々のT細胞の抗原特異性は異なる。個々の腫瘍関連抗原に対して最適な、すなわち個々の腫瘍関連抗原に対する反応性が高いTCRを選択するために、単一細胞ごとにcDNAを調製することが好ましい。
単離したTCRのcDNAを鋳型として増幅したPCR断片を、例えばギブソン・アッセンブリー・システムを用いて、ウイルスベクターまたは非ウイルスベクターに組み込むことができる。具体的には、ユビキチンプロモーターの下流に、単離したTCRα鎖遺伝子とTCRβ鎖遺伝子とをT2A配列を介して連結した遺伝子を結合し、さらにその下流に、IRES(internal ribosome entry site)配列に対してリガンド結合部位および細胞内ドメインを除いたEGFR(EGFRt、truncated EGFR)または細胞内ドメインを欠損するCD19等のマーカー遺伝子を連結し、この構築物をウイルスベクターまたは非ウイルスベクターに組み込む。ベクターとしては、ウイルスベクターおよび非ウイルスベクターを用いることができるが、非ウイルスベクターが好ましい。非ウイルスベクターとしては、トランスポゾンベクターが好ましく、piggyBac(登録商標)トランスポゾンベクターがさらに好ましい。トランスポゾン法は、従来のウイルスベクター法と比較して、安価で安全な次世代の遺伝子導入法である。
T細胞への分化状態が良好な非T非B細胞もしくは単球またはT細胞由来のiPS細胞クローン、前記iPS細胞クローンから分化した前記造血幹細胞、前記造血幹細胞から分化した前記未熟T細胞または前記未熟T細胞から分化した前記成熟T細胞へのTCRα鎖およびβ鎖をそれぞれコードするcDNA対を導入する方法としては、ウイルスベクターを用いる方法もしくは非ウイルスベクターを用いる方法またはゲノム編集技術を用いるTCRの置き換えのいずれも採用することができる。ウイルスベクターとしては、レンチウイルス、レトロウイルス、アデノウイルス、アデノ随伴ウイルス、ヘルペスウイルスおよびセンダイウイルス等のウイルスベクター、ならびに動物細胞発現プラスミドが挙げられるが、レトロウイルスまたはレンチウイルスが好ましい。レトルウイルスまたはレンチウイルス感染を行う場合は、スピンインフェクション法等を用いることが好ましい。非ウイルスベクターを用いる場合は、トランスポゾン法が好ましい。ゲノム編集技術を用いるTCRの置き換えには、CRISPR/Cas9法、CRISPR/MAD法およびCRISPR/CAS3法を用いてもよい。非ウイルスベクターの遺伝子導入方法またはゲノム編集のためのガイドRNAおよびドナーDNAの導入方法としては、リポフェクション法、リポソーム法、リン酸カルシウム共沈殿法、DEAEデキストラン法、マイクロインジェクション法およびエレクトロポレーション法が挙げられる。ベクターを用いずに、PCR産物を直接細胞に導入することもできる。トランスポゾンベクターまたはPCR産物の細胞導入には、エレクトロポレーション法を用いることが好ましい。エレクトロポレーション機器としては、遺伝子導入装置ExPERT(登録商標)システム(MaxCyte社)が好ましい。TCRα鎖およびβ鎖をそれぞれコードするcDNA対を導入する方法としては、CRISPR/Cas9およびTALEN等のゲノム編集技術を用いてもよい。CRISPR/Cas9によるTCR遺伝子の導入は、例えば、内在性TCRα鎖およびβ鎖の遺伝子中にデザインされたガイドRNA(センス鎖に対するガイドRNAおよびアンチセンス鎖に対するガイドRNA)、ならびに内在性TCRα鎖の相同組み換え部を5’側と3’側とに持つ目的のTCRα鎖およびβ鎖遺伝子をP2A配列 (自己切断部位)でつないだ遺伝子を、Cas9をコードするベクターとともに目的の細胞へ導入することにより達成される。この場合は、目的のTCRα鎖およびβ鎖遺伝子の発現に、内在性のプロモーターおよびエンハンサーが用いられる。
腫瘍関連抗原に対応するTCR対は、1エピトープあたりに5~10個と言われており、それぞれのTCR対は、腫瘍関連抗原の点変異変異体に対して異なる感受性を持つことが予測されている。したがって、例えば腫瘍関連抗原に点変異が起こった場合でも、前記エピトープを認識することのできるTCRが存在する可能性が高く、点変異変異体に対しても抗原に特異的な再生T細胞の準備を迅速に行うことができる。また、変異の結果、腫瘍関連抗原がまったく変化した場合であって、再生T細胞補充療法によるがん治療に耐性が生じた場合であっても、複数の腫瘍抗原に対する患者の反応性を解析し、それらの腫瘍関連抗原に応答するTCRを、すでに取得されているT細胞への分化能の高いiPS細胞またはiPS細胞由来の分化細胞から製造を開始できるため、迅速に再生T細胞を製造することが可能である。
腫瘍関連抗原に対応するTCR対の取得源となるT細胞は、腫瘍組織から採取することが好ましい。採取されたT細胞は、試験管内で腫瘍組織との共培養により腫瘍応答性の細胞集団を増幅した後、CD106をマーカーとして用いた細胞単離を行ってもよい。
本発明の再生T細胞を含有する医薬組成物は、がん治療対象を処置するために使用することができる。本発明の医薬組成物は、製剤技術分野において慣用の方法、例えば、日本薬局方に記載の方法等により製造することができる。本発明の医薬組成物は、薬学的に許容される添加剤を含んでいてもよい。該添加剤としては、例えば、細胞培養液、生理食塩水や適当な緩衝液(例えば、リン酸系緩衝液)等が挙げられる。
図1は、本発明の再生T細胞の製造工程を示す。治療を受けているがん患者(被験者)の腫瘍組織中の単核球を採取し、腫瘍抗原に特異的に反応するT細胞をCD106陽性T細胞として単離し、前記CD106陽性T細胞からTCR遺伝子を単離した(図1-(2'))。前記TCR遺伝子がコードするTCRの腫瘍への結合能より、より高い治療効果が期待されるTCR遺伝子を選択した(図1-(3'))。治療を受けている患者において腫瘍の再発および腫瘍細胞の変異が生じた場合には、治療に有効なTCR遺伝子を再度選択することが可能である。十分な治療効果を得るためには、TCRの種類(TCRレパトア)を多く取得することが重要である。
肝細胞がんまたは肝芽腫患者から採取された末梢血から、単核球分離溶液Lymphoprep(登録商標)を用いて単核球を単離した。得られた単核球から、CD19/CD20陽性のB細胞およびCD3/CD4/CD8陽性のT細胞を、FACSまたはMACSビーズを用いて除去し、非T非B細胞または単球を得た。得られた非T非B細胞または単球細胞集団に、山中4因子(Oct3/4、Sox2、Klf4およびc-Myc)を搭載したセンダイウイルス(CytoTune(登録商標)2.0)およびSV40Tagをコードしたセンダイウイルスを、5~20のMOI(multiplicity of infection)で感染させた。なおSV40は除いてもよい。
実施例2において得られた、T細胞への分化効率が良好な非T非B細胞または単球由来のiPS細胞クローンに対し、腫瘍抗原特異性が確認されたT細胞受容体α鎖およびβ鎖をコードした遺伝子を有するpiggyBac(登録商標)トランスポゾンベクターを、エレクトロポレーション法を用いて導入した。次に、目的のT細胞受容体α鎖およびβ鎖を発現するiPS細胞を、マーカー分子であるCD19の発現を指標に、セルソーターにより単離した。単離されたiPS細胞は、分化培地により約10日培養し、CD34/CD43ダブルポジティブの造血幹細胞を誘導し、セルソーターにより単離した。単離した血幹細胞は、FcDLL4でコートされたプレート上で約21日間培養し、T細胞への分化誘導を行った。
抗PD-1抗体が著効したメラノーマ患者において、抗PD-1抗体による治療開始前の手術検体から腫瘍組織を得た。得られた腫瘍組織に対してコラゲナーゼおよびDNaseを加え、37℃で30分間撹拌することにより酵素処理し、細胞を分離させた。腫瘍組織に由来する細胞と腫瘍浸潤免疫細胞との細胞混合物から、BD FACSAria III(登録商標)セルソーター(BD Biosciences社)を用いて、CD3陽性細胞をソートし、TCRを発現している細胞を得た。
実施例5と同様にして、腫瘍組織の細胞を分離し、得られた細胞混合物から、BD FACSAria IIIを用いてCD3陽性細胞をソートし、TCRを発現しているT細胞を腫瘍浸潤T細胞として得た。この腫瘍浸潤T細胞と、刺激剤として自己腫瘍から樹立した細胞株とを共培養し、IFN-γ産生を無刺激の場合と比較した。IFN-γ産生は、抗IFN-γ抗体を用いた細胞内染色により測定した。細胞染色は、抗PD-1抗体、抗TIGIT抗体、抗LAG3抗体、および抗CD106抗体を用いて行った。ネガティブコントロールとして、抗CD106抗体に対するアイソタイプ・コントロール抗体を用いた。
実施例2において得られた、T細胞への分化効率が良好な非T非B細胞または単球由来のiPS細胞クローンから、造血幹細胞および未熟T細胞を経由して分化した成熟T細胞に対し、GPC3抗原特異的T細胞受容体α鎖β鎖をコードする遺伝子(cDNA)を、piggyBac(登録商標)システムを用いて、実施例3と同様にして導入した。
図11は、末梢血T細胞を初期化したiPS細胞から再生T細胞を製造する工程において、T細胞への分化効率が高いiPS細胞クローンを選別する方法を示す。EBV(Epstein-Barrウイルス)に感染者した被験者の末梢血より単核球を分離し、分離した単核球を、試験管内でEBV抗原により刺激し、EBV抗原を認識するCD8陽性T細胞集団を単離した。単離したCD8陽性T細胞集団に、山中4因子(Oct3/4、Sox2、Klf4およびc-Myc)およびSV40T抗原を、センダイウイルスベクターを用いて導入し、iPS細胞集団を得た。得られたiPS細胞集団からiPS細胞クローンを分取し、それぞれのクローンについて、T細胞への分化能を調べ、T細胞への分化効率が高いiPS細胞クローンを選別した。EBV抗原を認識するT細胞は、同種移植を行った場合であっても、アロ反応を生じにくい細胞である。
Claims (28)
- (1)被験者から得られるT細胞であって、腫瘍関連抗原に対して反応性を有し、かつCD106陽性T細胞集団から、単一細胞ごとに、T細胞受容体α鎖およびβ鎖をそれぞれコードするcDNAを調製する工程、
(2)被験者の末梢血単核球であって、B細胞およびT細胞が除去された末梢血単核球またはT細胞をiPS細胞に初期化し、得られたiPS細胞からT細胞への分化効率が高いiPS細胞クローンを選別する工程、
(3)前記cDNAを、前記iPS細胞クローン、前記iPS細胞クローンから分化した造血幹細胞、前記造血幹細胞から分化した未熟T細胞または前記未熟T細胞から分化した成熟T細胞に導入する工程、および
(4)工程(3)において得られた、前記cDNAが導入された前記iPS細胞クローン、前記造血幹細胞または前記未熟T細胞の成熟T細胞への分化および前記成熟T細胞の増殖を行う工程、
を含む、iPS細胞を介する再生T細胞の製造方法。 - 工程(2)の実施が、工程(1)の実施に先行する、または工程(1)の実施と並行する、請求項1に記載の方法。
- 工程(1)および(2)における被験者が、同一個体であって、がんの予防または治療対象である、請求項1または2に記載の方法。
- 工程(1)および(2)における被験者が、互いに別個体であって、工程(2)における被験者が、がんの予防または治療対象である、請求項1または2に記載の方法。
- 工程(1)および(2)における被験者が、互いに別個体であって、工程(1)における被験者が、がんの予防または治療対象である、請求項1または2に記載の方法。
- 工程(1)および(2)における被験者が、同一個体または互いに別個体であって、工程(1)および(2)における被験者とは異なる被験者が、がんの予防または治療対象である、請求項1または2記載の方法。
- さらに、工程(4)において得られる前記cDNAが導入されたT細胞から、がんの予防または治療対象である被験者に由来する細胞に対してアロ反応を示さないT細胞を選別する工程を含む、請求項1または2に記載の方法。
- さらに、工程(1)で調製されたcDNAから、がんの予防または治療対象である被験者に由来する細胞に対してアロ反応を誘導しないT細胞受容体をコードするcDNAを選別する工程を含む、請求項1または2に記載の方法。
- がんの予防または治療対象である被験者に由来する前記細胞が、末梢血単核球である、請求項7または8に記載の方法。
- 工程(3)において、前記iPS細胞クローン、前記iPS細胞クローンから分化した前記造血幹細胞、前記造血幹細胞から分化した前記未熟T細胞または前記未熟T細胞から分化した前記成熟T細胞への前記cDNAの導入が、ウイルスベクターもしくは非ウイルスベクターを用いる、またはゲノム編集技術を用いる、請求項1~9のいずれか1項に記載の方法。
- 前記ゲノム編集技術が、CRISPR/Cas9またはTALENである、請求項10に記載の方法。
- 前記非ウイルスベクターが、トランスポゾンベクターである、請求項10に記載の方法。
- 前記トランスポゾンベクターが、piggyBac(登録商標)トランスポゾンベクターである、請求項12に記載の方法。
- 工程(4)において、前記cDNAが導入された前記iPS細胞クローン、前記造血幹細胞または前記未熟T細胞の成熟T細胞への分化および前記成熟T細胞の増殖を行う工程が、フィーダー細胞およびPHA(phytohemagglutinin)の存在下、レトロネクチン(登録商標)および抗CD3抗体の存在下、または抗CD3抗体および抗CD28抗体の存在下で行われる、請求項1~13のいずれか1項に記載の方法。
- 前記フィーダー細胞が、自家または他家の末梢血単核球である、請求項14に記載の方法。
- 工程(1)または(2)における前記被験者が、肝細胞がん、肝芽腫、胃がん、食道がん、肺がん、膵臓がん、腎細胞がん、乳がん、卵巣がん、悪性黒色腫などの皮膚がん、膀胱がん、頭頸部がん、子宮がん、子宮頸がん、膠芽腫、前立腺がん、神経芽腫瘍、慢性リンパ性白血病、甲状腺乳頭がん、大腸がん、脳腫瘍、肉腫またはB細胞非ホジキンリンパ腫の患者である、請求項1~15のいずれか1項に記載の方法。
- 工程(1)または(2)における前記被験者が、免疫原性の高いがんの患者である、請求項1~15のいずれか1項に記載の方法。
- 前記免疫原性の高いがんが、肝細胞がん、肝芽腫、大腸がん、肺がんまたは悪性黒色腫である、請求項17に記載の方法。
- 工程(1)における前記T細胞集団が、CD3/CD106ダブルポジティブである、請求項1~18のいずれか1項に記載の方法。
- 前記造血幹細胞が、CD34/CD43ダブルポジティブである、請求項1~19のいずれか1項に記載の方法。
- 前記未熟T細胞が、CD8α鎖/β鎖ダブルポジティブである、請求項1~20のいずれか1項に記載の方法。
- 工程(2)において選別された、T細胞への分化効率が高いiPS細胞クローン、または工程(3)における前記iPS細胞クローンから分化した造血幹細胞、前記造血幹細胞から分化した未熟T細胞または前記未熟T細胞から分化した成熟T細胞を保存し、マスターセルバンクを構成する、請求項1~21のいずれか1項に記載の方法。
- 前記保存が凍結保存である、請求項22に記載の方法。
- 前記マスターセルバンクに保存された前記iPS細胞クローン、前記造血幹細胞、前記未熟T細胞または前記成熟T細胞に対して、工程(3)および(4)を行う、請求項22に記載の方法。
- 前記iPS細胞クローン、前記造血幹細胞、前記未熟T細胞または前記成熟T細胞を含む、請求項22に記載のマスターセルバンク。
- 請求項1~24のいずれか1項に記載の方法により製造された再生T細胞。
- 請求項26に記載の再生T細胞を含有する医薬組成物。
- 請求項27に記載の医薬組成物を用いる、がんの予防または治療方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21915348.3A EP4273234A1 (en) | 2021-01-04 | 2021-12-29 | Method for producing regenerated t cell via ips cell |
CN202180088550.1A CN116744947A (zh) | 2021-01-04 | 2021-12-29 | 一种通过iPS细胞生产再生T细胞的方法 |
US18/259,687 US20240052309A1 (en) | 2021-01-04 | 2021-12-29 | Method for producing regenerated t cell via ips cell |
JP2022573131A JPWO2022145490A1 (ja) | 2021-01-04 | 2021-12-29 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-000176 | 2021-01-04 | ||
JP2021000176 | 2021-01-04 | ||
JP2021070534 | 2021-04-19 | ||
JP2021-070534 | 2021-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022145490A1 true WO2022145490A1 (ja) | 2022-07-07 |
Family
ID=82260848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/049028 WO2022145490A1 (ja) | 2021-01-04 | 2021-12-29 | iPS細胞を介する再生T細胞の製造方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240052309A1 (ja) |
EP (1) | EP4273234A1 (ja) |
JP (1) | JPWO2022145490A1 (ja) |
WO (1) | WO2022145490A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013176197A1 (ja) | 2012-05-22 | 2013-11-28 | 国立大学法人 東京大学 | 抗原特異的t細胞の製造方法 |
WO2016010148A1 (ja) * | 2014-07-18 | 2016-01-21 | 国立大学法人京都大学 | 多能性幹細胞から免疫細胞療法用t細胞を誘導する方法 |
WO2017179720A1 (ja) * | 2016-04-15 | 2017-10-19 | 国立大学法人京都大学 | Cd8陽性t細胞を誘導する方法 |
WO2018182817A1 (en) * | 2017-03-29 | 2018-10-04 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
WO2021006316A1 (ja) * | 2019-07-10 | 2021-01-14 | 国立研究開発法人国立がん研究センター | がん細胞を特異的に攻撃しているt細胞を同定するための特異的マーカー |
-
2021
- 2021-12-29 WO PCT/JP2021/049028 patent/WO2022145490A1/ja active Application Filing
- 2021-12-29 JP JP2022573131A patent/JPWO2022145490A1/ja active Pending
- 2021-12-29 US US18/259,687 patent/US20240052309A1/en active Pending
- 2021-12-29 EP EP21915348.3A patent/EP4273234A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013176197A1 (ja) | 2012-05-22 | 2013-11-28 | 国立大学法人 東京大学 | 抗原特異的t細胞の製造方法 |
WO2016010148A1 (ja) * | 2014-07-18 | 2016-01-21 | 国立大学法人京都大学 | 多能性幹細胞から免疫細胞療法用t細胞を誘導する方法 |
WO2017179720A1 (ja) * | 2016-04-15 | 2017-10-19 | 国立大学法人京都大学 | Cd8陽性t細胞を誘導する方法 |
WO2018182817A1 (en) * | 2017-03-29 | 2018-10-04 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
WO2021006316A1 (ja) * | 2019-07-10 | 2021-01-14 | 国立研究開発法人国立がん研究センター | がん細胞を特異的に攻撃しているt細胞を同定するための特異的マーカー |
Non-Patent Citations (7)
Title |
---|
MINAGAWA A ET AL.: "Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy", CELL STEM CELL, vol. 23, 2018, pages 850 - 858 |
MINAGAWA ATSUTAKA; YOSHIKAWA TOSHIAKI; YASUKAWA MASAKI; HOTTA AKITSU; KUNITOMO MIHOKO; IRIGUCHI SHOICHI; TAKIGUCHI MAIKO; KASSAI Y: "Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy", CELL STEM CELL, ELSEVIER, CELL PRESS, AMSTERDAM, NL, vol. 23, no. 6, 6 December 2018 (2018-12-06), AMSTERDAM, NL , pages 850, XP085555973, ISSN: 1934-5909, DOI: 10.1016/j.stem.2018.10.005 * |
NISHIMURA T ET AL.: "Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation", CELL STEM CELL, vol. 12, 2013, pages 114 - 126, XP055567898, DOI: 10.1016/j.stem.2012.11.002 |
NIWA A ET AL., J CELL PHYSIOL., vol. 221, no. 2, November 2009 (2009-11-01), pages 367 - 77 |
NIWA A ET AL., PLOS ONE, vol. 6, no. 7, 2011, pages e22261 |
R. K. LINDEMANN ET AL., MOL. CANCER, vol. 2, 2003, pages 20 |
TAKAYAMA N. ET AL., J EXP MED., 2010, pages 2817 - 2830 |
Also Published As
Publication number | Publication date |
---|---|
EP4273234A1 (en) | 2023-11-08 |
US20240052309A1 (en) | 2024-02-15 |
JPWO2022145490A1 (ja) | 2022-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11578310B2 (en) | Method for producing CD4/CD8 double-positive T cells | |
JP2022078215A (ja) | 多能性幹細胞からhlaホモ接合免疫細胞への指向分化方法 | |
EP3572502B1 (en) | Method for producing cd8alpha +beta + cytotoxic t cells | |
JP2023516632A (ja) | 多能性幹細胞からナチュラルキラー細胞を産生するための方法 | |
WO2020027094A1 (ja) | iPS細胞を介して再生T細胞集団を製造する方法 | |
WO2016010155A1 (ja) | 抗原特異的t細胞受容体遺伝子を有する多能性幹細胞の製造方法 | |
WO2022059780A1 (ja) | iPS細胞を介する再生T細胞の製造方法 | |
WO2016010153A1 (ja) | 免疫細胞療法用t細胞の誘導方法 | |
US20200345789A1 (en) | Production method for ips cell-derived population of genetically diverse t cells | |
JP2024095758A (ja) | T細胞受容体の改変体 | |
US20180298337A1 (en) | Method for producing cd4-positive t cells from pruripotent stem cells | |
WO2022220146A1 (ja) | T細胞受容体遺伝子を導入するためのiPS細胞により構成される細胞バンク | |
TW202345878A (zh) | 控制性t細胞之製造方法 | |
US20220233665A1 (en) | Medicinal composition | |
WO2022145490A1 (ja) | iPS細胞を介する再生T細胞の製造方法 | |
CN116744947A (zh) | 一种通过iPS细胞生产再生T细胞的方法 | |
WO2024071411A1 (ja) | iPS細胞から誘導された免疫細胞 | |
TW202421780A (zh) | T細胞的製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21915348 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022573131 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180088550.1 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021915348 Country of ref document: EP Effective date: 20230804 |